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Abstract 
This PhD thesis is focused on two main topics: 
 
Part A. Total synthesis, biological evaluation and SAR 
studies of Smo and Gli antagonists 
 
Hedgehog (Hh) signaling pathway is essential for tissue homeostasis, 
development and stemness. Since Hh pathway possesses a critical role 
in cancer initiation, proliferation, metastasis, chemoresistance and in 
the survival of CSCs, its constituents represent attractive druggable 
targets for anticancer therapy. With the aim to inhibit the pathway at 
the upstream receptor Smoothened (Smo) or the downstream effector 
Gli1, small molecules as emerged as promising anticancer agents. 
The natural isoflavone Glabrescione B (GlaB) emerged as the first 
small molecule binding to Gli1 zinc-finger and debilitating Gli1 
activity by interfering with its interaction with DNA. 
 Here, taking advantage by the versatile isoflavone scaffold, we have 
designed, synthesized and tested new Hh inhibitors. The rational 
introduction of defined substitutions on the isoflavone’s ring B, led us 
to identify molecules targeting preferentially Gli1 or Smo. Thanks to 
a multidisciplinary approach, combining chemical, biological and 
molecular docking fields, it was possible obtain new insights into the 
mechanism of action of these molecules. The co-administration of two 
different isoflavones behaving as Smo and Gli antagonists in primary 
mudulloblastoma (MB) cells, emphasized the synergistic effects of 
these agents, hence paving the way to additional and innovative 
strategies for the pharmacological inhibition of Hh signaling.  
 
Part B. Toward the total synthesis of madangamine B 
 
Marine natural products show increasing interest in biological, 
ecological, pharmacological and chemical fields. Since their 
secondary metabolites possess structures not identified in terrestrial 
organisms, endowed by significant biological activities, they are 
intriguing candidates as lead compound for drug discovery. 
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Madangamines (A-F), a class of diazapentacyclic alkaloids, were 
discovered (A-E) by Andersen and co-workers since 1992 from a 
sponge of the genus Haposclerida, family Petrosiidae, collected off 
Madang, in Papua New Guinea. The same authors reported in 1994 
the isolation of madangamine A, found in the marine sponge 
Xestospongia ingens, and few years later they described four new 
related alkaloids, labelled madangamines B-E. It had to wait until 
2005 to reach the isolation of madangamine F from Pachychalina 
alcaloidifera, accomplished by Berlinck and co-workers and reported 
in 2007.  
Pure madangamines A-C and F were isolated as optically active 
compounds; madangamines D and E were isolated as inseparable 
mixture. 
Until 2014 the absolute configuration of madangamines was only 
presumed, and it has been hypothesized on the basis of an ingenamine, 
which is considered a putative precursor of madangamines. 
 
The assignment of the absolute configuration of (+)-madangamine D 
is based on its first total synthesis by Amat and co-workers. As had 
been described for the natural products, synthetic madangamine D has 
been found dextrorotatory, having unambiguous 2S, 5S, 9R, 12R 
absolute configuration of this alkaloid family. 
Madangamines A and F exhibited, in vitro, M IC50 values against a 
multitude of cancer cell lines, both human and murine’s ones. Thanks 
to the collaboration with PharmaMar Company it was been possible 
test the activity of madangamine D, that exhibited in vitro significant 
cytotoxic activity against pancreas (GI50 7.4 μg/mL) and colon cancers 
(GI50 4.4 μg/mL). 
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Part A 
 
 
Total synthesis, biological evaluation, and SAR 
studies of Smo and Gli antagonists 
 
 
 
 
 
 
 
 
 
The present part of the thesis deals with a research activity carried out at the 
Dipartimento di Chimica e Tecnologie del Farmaco at Sapienza Università 
di Roma, under the supervision of Prof. Bruno Botta. 
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A1.1 Natural Products as Anticancer Agents 
 
Modern pharmaceutical research strongly relies on the 
investigation and identification of innovative lead compounds. In this 
context, natural products have proven to be extremely promising for 
anticancer drug discovery. 
 
In the 1950s, the U.S. National Cancer Institute (NCI) established 
a screening of about 35000 plant samples to rate their growth 
inhibitory effects against the mouse leukemia cell lines L1210 and 
P388, respectively. From this screening, paclitaxel (TaxolTM), isolated 
from the bark of the Pacific yew Taxus brevifolia, emerged as the most 
significative drug. By 1985, the NCI carried on that screening against 
60 human cancer cell lines, including cell lines derived from solid 
cancers (i. e. lung, colon, skin, ovary, brain, prostate cancers, leukemia 
too). In such screening were entailed extracts from plants, animals, 
microorganisms and co-products derived from microorganisms of 
marine origin1. NCI research to support the discovery of new natural 
anticancer agents is still ongoing. 
To give a practical example of the importance of natural products 
in anticancer therapy, by 2010, the 52% of the 178 new drugs 
approved for the treatment of cancers are originated from natural 
products. In particular, 14% are non-modified natural products, 27% 
modified natural products, and 11% synthetic compounds obtained 
after natural product optimization2. The latter point emphasizes the 
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role of natural products as suitable templates for drug design; in fact, 
even if a natural product is not an effective drug itself, it still may be 
a good starting material for further improvements. 
The major problem encountered during the development of 
natural products as new drugs is to find out a scalable and inexpensive 
route to obtain the desired material. Extraction processes allow to 
achieve very low quantities of natural product. The problem should be 
overcome by large-scale fermentation, but for some organisms it is not 
so easy. On the other hand, the chemical synthesis of natural 
compounds and their analogues could be very effective to solve the 
abovementioned problems; especially, the total synthesis allows the 
preparation of natural product derivatives employable for the 
structure-activity-relationship (SAR) studies, which are very difficult 
to perform on semi-synthetic intermediates3. 
In conclusion, the abundance of substances driven by plants and 
marine organisms allows us to exert them as starting products as drug 
design templates. 
  
  6 
 
A1.2 Inhibition of the Hedgehog Signaling Pathway: a 
Challenge Posed by Natural products 
 
A1.2.1 Cancer Stem Cells Theory 
 
A1.2.1.1 The Hypotesis 
 
Even if the concept that cancer might arise from a population of stem-
like cells was proposed about 150 years ago, only in the last 40 years 
cancer research has demonstrated that tumor cells are very different. 
The official definition is4: 
“A cell within a tumor that possess the capacity 
To self-renew and to cause the heterogeneous 
Lineages of cancer cell that comprise the tumor4”.  
 
Cancer stem cells (CSCs) can thus be defined experimentally by 
their ability to regenerate a continuously growing tumor. 
Heterogeneous populations of cancer cells at various differentiation 
stages could be the result of both acquired mutations and aberrant but 
hierarchical differentiation schemes. Cancer is both a differentiation 
and a proliferation disease, and the ‘clonal evolution’ and ‘cancer stem 
cell’ models might not be mutually exclusive, as initially thought. 
Owing to genetic instability, the tumor-initiating cells isolated from a 
clinically detectable tumor would probably have an essentially 
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different genomic pattern from the initial transformed cells that 
originated the tumor5. 
CSCs habitually display resistance to traditional chemotherapy 
and they seem to be responsible of cancer initiation, recurrence and 
metastasis, due to their asymmetric divisions, ability to drug efflux, 
immortality, and mesenchymal phenotype. Hence, the possibility to 
identify and isolate these cells has provided a promising opportunity 
for novel therapeutic strategies that tender the conventional cancer 
therapy a tip of the iceberg of anticancer approach. A salient point in 
this context is that proliferation is not synonymous with self-renewal; 
a self-renewing cell division results in one or both daughter cells 
which have essentially the same ability to replicate and generate 
differentiated cell descents as the parental cell. Stem cells have the 
ability to undergo a symmetrical self-renewing cell division, causing 
identical daughter stem cells, which preserve self-renewal capability, 
or an asymmetrical self-renewing cell division, resulting in one stem 
cell and more differentiated progenitor cells. As well, it seems that 
stem cells may divide symmetrically to form two progenitor cells, 
which could lead to stem cell depletion4. This form of division would 
be a way to deplete the cancer stem population and may constitute a 
promising strategy to inducing cell death in cancer4. 
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A1.2.1.2 Therapeutic Strategies 
 
At the moment, various therapeutic strategies are able to target 
tumor-initiating cells. Killing these cells can be accomplished by 
inhibiting their survival pathways or sensitizing them to 
chemotherapeutic agents. Current failure with cancer treatment is not 
usually due to the lack of primary response or initial induction of 
remission, but to relapse or tumor recurrence after therapy, in which 
tumor-initiating cells seem to play a critical role. If therapies can be 
targeted against CSCs, this will tender the tumor unable to maintain 
themselves or grow. The promising approaches to kill tumor-initiating 
cells include blocking essential self-renewal signaling, inhibiting the 
survival mechanisms of these cells, or targeting tumor-initiating cell 
surface markers through antibody-based cytotoxic approaches6. 
Alternatively, differentiating the CSCs might be a successful 
therapeutic strategy as the bulk of the tumor has limited proliferative 
potential7. 
Obviously, targeting CSCs alone may not be sufficient to get 
effective cures or long-term remission for most cancers; a promising 
solution to eradicate both cancer cells and cancer stem cells is 
represented by a combined therapy, using both conventional 
chemotherapeutic drugs with an agent capable to target CSCs. 
Additionally, since the use of active agents targeting a single hit might 
lead to resistance phenomena, the most rational solution to target 
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CSCs is represented by the employment of a multi-target anti CSCs 
therapy8 (Figure 1). 
 
Figure 1 Conventional therapies vs CSCs therapies9 (Reproduced with permission). 
Several signaling pathways that regulate normal stem cells can 
cause neoplastic proliferation when dysregulated by mutation. In 
tumor initiating cells those pathways may be constitutively activated 
or improperly regulated, leading to uncontrolled growth. 
Developmental signaling pathway responsible for normal stem cell 
self-renewal, including Wnt, Hedgehog (Hh) and Notch have been 
shown to be active in several cancers12 (Figure 2).  
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Figure 2 Wnt, Shh and Notch pathways: their contribution in the self-renewal of stem 
cells and/or progenitors, and in tumorigenesis10 (Reproduced with permission). 
 
A1.3 The Hedgehog Signaling Pathway 
 
The Hh signaling pathway controls tissue polarity, patterning and 
stem cell maintenance. In 1980 Christiane Nusslein-Volhard and Eric 
F. Weischaus identified the Hedgehog gene (Hh) by genetic screens in 
Drosophila Melanogaster. It earned its name from the appearance of 
embryos with null alleles of Hh, which display a larval of 
disorganized, hair-like bristles reminiscent of hedgehog spines. The 
vertebrate genome duplication has resulted its expansion of the Hh 
genes, which can be classified into: Desert (Dhh), Indian (Ihh) and 
Sonic (Shh) groups. The Shh activity and effects are the largest studied 
in vertebrates field. 
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A1.3.1 The Pathway 
 
The precise mechanism of Hh signaling pathway is not totally 
understood. Hh pathway activation starts when the ligand Hh, released 
from the cells through the transmembrane transporter Dispatched, 
binds the transembrane receptor Patched1 (Ptch1). Constitutively, 
Ptch1 inhibits the membrane receptor Smoothened (Smo) by 
preventing its location to the primary cilium (Figure 3a). In the 
presence of Hh, the Ptch1 loses its inhibitory activity against Smo, Hh-
Ptch1 complex is internalized, allowing Smo activation. Translocation 
of Smo to the primary cilium originates a signaling cascade leading to 
the activation of glioma associated oncogene (Gli) family of zinc-
finger transcription factors (Gli1, Gli2 and Gli3), the final effectors of 
the pathway. In vivo, Gli1 acts predominantly as an activator, Gli3 acts 
predominantly as repressor and Gli2 possesses both repressive and 
activator functions. Activated Glis translocate into the nucleus to 
induce the expression of various specific genes, such as those 
encoding the D-type cyclins, c-MYC (also knowns as MYC), BCL2 and 
SNAIL (also called SNAI), which regulate cellular differentiation, 
proliferation and survival13, 14. Moreover, Hh target genes include 
Gli1, PTCH1, and the gene encoding Hh-interacting protein15. The 
signaling of Gli is also regulated by several protein mediators (PKA, 
GSK3-, CK1-) including suppressor of fused (SuFu). SuFu behaves 
as a negative regulator of the Hh pathway by sequestering Gli in the 
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cytoplasm, thus repressing transcriptional activation by these factors16, 
17 (Figure 3b). 
 
 
Figure 3 Hh pathway activation. (a) Inactive Hh pathway. (b) Activated Hh pathway18 
(Reproduced with permission). 
 
A1.3.2 Alteration of the Hedgehog Pathway and Cancer  
 
In recent years, several studies emphasized with disarmingly 
clarity the correlation between the aberrant activation of the Hh 
pathway and cancer.  
Meanwhile during the embryonic phase Hh is fundamental in 
development and tissue homeostasis, in adults the pathway is activated 
during tissue repairing19. Hh pathway mutation or dysregulation in 
adults plays a crucial role in the proliferation and differentiation, 
inducing to tumorigenesis or tumor growth acceleration. Basal cell 
carcinoma (BCC) and medulloblastoma (MB) are two well-
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recognized cancers with mutations in components of the Hh pathway. 
Inappropriate activation of the Hh signaling pathway has been 
implicated in the development of several other types of cancer 
including lung, prostate, breast, and pancreas, as examples20-22. 
According to recent suggestions, it seems that Hh might also promote 
tumorigenesis by signaling in a paracrine manner from the tumor to 
surrounding stroma, or in cancer stem cells. 
Three basic models have been proposed for the Hh pathway 
activity in cancer (Figure 4)13, 23. 
 
 Type I: ligand-independent  
The first discovered were the type I cancers harbouring Hh 
pathway-activating mutations which are Hh ligand independent, such 
as BCCs and MBs (figure 4a). Most of these tumors either had 
inactivating mutations in Ptch1 (85%) or activating mutations in Smo 
(10%)24. Furthermore, about one third of all medulloblastomas and 
occasional rhabdomyosarcomas were shown to have inappropriate Hh 
pathway activation, often due to Ptch1 mutations or sometimes due to 
SuFu mutations25, 26. Since these tumors are ligand independent, Hh 
pathway inhibitors must act at or below the level of Smo to be 
effective. 
 
 Type II: ligand-dependent autocrine mechanism 
Autocrine activation of the Hh pathway in tumor cells through 
increased Hh ligand expression has been reported in a variety of 
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tumors, such as lung, breast, stomach and prostate cancers27 (Figure 
4b). The relevance of this mechanism is not clearly understood, and 
most of these tumors are dissimilar to BCC or MBs; indeed they do 
not harbor any somatic mutations in the Hh signaling pathway. Rather, 
they demonstrate an autocrine, ligand-dependent, abnormal Hh 
pathway activation. Most of these tumors have an elevated expression 
of the Hh ligand (Shh or Ihh) and/or ectopic Ptch1 and Gli expression 
within the epithelial compartment. This autocrine tumor growth can 
be effectively suppressed by various pathway inhibitors such as Hh 
neutralizing antibodies or Smo antagonists. 
 
 Type III: ligand-dependent paracrine mechanism 
 
In contrast to the autocrine model, Bushman and colleagues were 
the first to propose that at least one model of prostate cancer signals in 
a paracrine manner to the stroma28. In paracrine signaling, Hh 
produced by the tumor cells is received by the stroma, which feeds 
other signals back to the tumor to promote its growth or survival 
(Figure 4c). The precise mechanisms by which the Hh-stimulated 
stroma positively regulates tumor cell growth are not completely 
understood.  
However, it has been proposed that Hh regulates signaling 
mediators in the stroma, including insulin-like growth factor (IGF), 
Wnt, interleukin-6 (IL-6) and vascular endothelial growth factor 
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(VEGF), which in turn promote tumor growth. Inhibition of this 
paracrine signaling in epithelial tumors may be of therapeutic value, 
as specific inhibition of Hh signaling in the stroma did result in growth 
inhibition of tumor xenografts, although the most effective way of 
treating these tumors would possibly be to use a combination of a Hh 
pathway inhibitor to target the stroma and other drugs to target the 
tumor cells. 
 
 Tipe IIIb: reverse paracrine mechanism 
Very recently, a “reverse paracrine” signaling model has also been 
recognized in which Hh is secreted from the stroma and is received by 
the tumor cells (Figure 4d). In this model, stromal Hh is thought to 
provide the appropriate microenvironment for potentiating tumor 
growth and would thus be a suitable therapeutic target as well27.  
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Figure 4 Different models of Hedgehog pathway activation in cancers. (a) Type I 
ligand-independent cancers. (b) Type II ligand-dependent autocrine cancers. (c) Type 
III ligand-dependent paracrine cancers. (d) Type IIIb reverse paracrine tumors18 
(Reproduced with permission). 
 
A1.4 Hedgehog Pathway and Cancer Stem Cells 
 
Considerably, Hh signaling is active in CSCs of various types of 
cancer, sustaining the proliferation of these cells, which are considered 
responsible of tumor relapse and resistance to conventional anticancer 
therapies. In fact, the Hh pathway controls the functional properties of 
CSCs, such as self- renewal, survival, metastatic spread, and 
neoangiogenesis, by the regulation of stemness-determining genes 
such as Nanog, often overexpresses in cancer. Since increasing 
evidences support the crucial role of the Hh pathway in cancer 
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initiation, proliferation, metastasis, chemoresistance, and in the 
survival of CSCs19, 29, its components represent attractive druggable 
targets for anticancer therapy. 
 
 
Figure 5 Hedgehog pathway and CSCs. 
 
With the aim to optimize the therapeutic benefit in anticancer 
treatment, it might be crucial to understand the specific mechanism of 
Hh activation in cancer desease. Four major modes of Hh inhibition 
have been exploited therapeutically: 
 SMO inhibition; 
 Receptor-ligand disruption; 
 Inhibition of ligand processing; 
 Gli inhibition (Figure 6). 
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Figure 6 Potential sites for blocking the Hh pathway with therapeutic agents18 
(Reproduced with permission). 
 
A1.4.1 Smo Inhibitors 
 
In recent years, drug discovery efforts directed against the Hh 
pathway and focused predominantly on the development of Smo 
antagonists. A remarkable number of small molecules of natural, 
semisynthetic or synthetic origin have been developed and extensively 
reviewed30. 
The mechanism of Smo regulation during Hh signaling is still 
obscure. It is well known that Smo is a seven transmembrane protein 
and exists in conformational switch, converting between an ‘open and 
active’ to a ‘closed and inactive’ form31, 32. This equilibrium is 
controlled by a ligand, whose identity has remained elusive. Among 
the Smo inhibitors, cyclopamine (natural alkaloid), vismodegib and 
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sonidegib (approved by FDA in 2012 and 2015, respectively, for 
treatment of metastatic and locally advanced BCC) are noteworthy. 
Despite the initial enthusiasm, clinical development of Smo 
antagonists has ultimately proved disappointing, due to scarce 
pharmacokinetics, low selectivity on CSCs, severe side effects, and 
the emergence of drug resistance30. Advanced tumors can evolve 
resistance through pathway-dependent genetic mechanisms or through 
compensatory adaptation. Pathway-dependent genetic alterations, 
discovered in resistant tumors from patients and animal models, 
directly affect Hh pathway members. In particular, the resistance 
toward vismodegib originates from genetic alteration at the level of, 
or downstream from, Smo. Resistance can originate from Smo point 
mutations that ablate Smo-drug interaction while maintaining Hh 
pathway avtivation33 (Figure 7a). These mutations occur in the ligand-
binding pocket of Smo. Other genetic aberrations that drive to 
resistance come from gene duplications of Gli2 or Hh target gene 
cyclin D1 (Figure 7b), able to bypass the requirement of Smo to 
inappropriately maintain or increase Gli target gene induction. These 
mutations encourage both Hh pathway activation in the presence of 
Smo antagonists, and mediate tumor growth. 
Compensatory alterations outside the Hh pathway have been 
individuated to mediate tumor resistance; this is the case in which Hh 
activation occurs in the absence of a direct genetic mutation or copy 
number of variation of Hh members, and is epigenetic in nature. 
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Recently, the development of Hh inhibitors able to modulate 
targets acting downstream of Smo, or independently by Smo (Gli), 
might represent a promising therapeutic strategy for the treatment of 
Hh dependent tumors. This strategy would allow overcoming anti-
Smo resistance and adverse effects, which are responsible for more 
than 50% dropout’s rates in Smo antagonists clinical trials. 
 
Figure 7 Genetic escape pathways evolving during Smo antagonist treatment and 
approaches to overcome resistance. (a) Smo point mutations. (b) Gli target gene 
amplification of Gli2. Compensatory escape pathways including (c) PI3K pathway 
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up-regulation or (d) inappropriate activation of aPKC-/18 (Reproduced with 
permission).  
 
A1.4.2 Gli Inhibitors 
 
Gli transcription factors (Gli1, activator, Gli2 and Gli3 both 
activators or repressors) represent the final effectors of the Hh 
pathway and share common structural features, such as five highly 
conserved tandem zinc fingers (ZFs), a conserved N-terminal domain, 
potential protein kinase A (PKA) binding sites, and additional 
conserved region at the C-terminus. 
It is important to consider that, whatever alteration leads to 
aberrant Hh pathway activation, such as genetic mutations of pathway 
components or other Smo-dependent or -independent mechanisms, all 
trigger the down-stream effector of Gli1. For this reason, Gli factors 
are recently emerging as attractive targets for the development of 
novel anticancer drugs. 
Nowadays, two distinct classes of Gli antagonists have been 
identified: 
 direct Gli antagonists (able to inhibit Gli transcriptional 
functions through a direct contact); 
 indirect Gli antagonists (the inhibition is afforded by 
arresting of mechanisms that control Gli activities). 
The first Gli antagonists discovered by Lauth et al. in 2007 were 
GANT58 (I) and GANT61 (II)34 (Figure 8). Compound II has become 
the lead compound in many biological studies, since it proved to 
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inhibit the Hh pathway in five different human colon carcinoma cell 
lines and in prostate cancer human xenografts. Recently, the HPIs 
(Hedgehog Pathway Inhibitors) (III-VI) were identified by Chen and 
co-workers as Gli antagonists35. HPI-1 is the most promising 
compound, and it was encapsulated in a polymeric nanoparticle. 
Arsenic trioxide (ATO) (VII) is a drug approved by FDA for the 
treatment of promyelocytic leukemia; it resulted effective both in vivo 
and in vitro and acts interfering directly with the Gli transcriptional 
factors36 (Figure 8). Since 2013, ATO is the protagonist of a clinical 
trial study, in order to investigate its efficacy in treating patients with 
BCC. 
 
Figure 8 Gli direct antagonists. 
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In conclusion, Gli transcriptional factors represent the most 
promising target for the development of new drugs targeting the Hh 
pathway in tumors. A significant contribution to the discovery of 
novel Hh inhibitors is given by natural products.  
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A2.1 Gli1/DNA Interaction: Identification of the Biding Site 
 
The beginning of the investigation on Gli1’s active site was based 
on the available X-ray structure of cobalt ion-coordinated GliZF in 
complex with DNA37, 38. A representative GliZF structure was 
extracted after molecular dynamics (MD) simulations for further 
ligand design in silico (Figure 9a). Based on MD analysis and X-ray 
structure, a computational alanine scanning was carried out to verify 
which basic aminoacidic residues in ZF4 and ZF5 domains are 
responsible of the thermodynamic stability of the Gli1ZF/DNA 
adduct34. The delta energy (G) of binding to DNA of Gli1 mutants 
(Figure 10b) and wild-type Gli1ZF (Gli1ZF-WT) (G) were 
calculated. Basic aminoacid residues in ZF4 (K340, K350, R354) and 
ZF5 (K360, K371, R380 and K381) domains showed the strongest 
G contribution (Figure 9b), suggesting their crucial role in 
Gli1/DNA interaction37. 
 
 
Figure 9 Structure-based analysis of Gli1/DNA complex. (A) Gli1ZF/DNA structure 
extrapolated from MD analysis. Gli1ZF (blue cartoon), residues involved in binding 
to DNA (magenta sticks), Zn ions (grey spheres) are shown. (B) Effect of Gli1ZF 
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mutants on the binding affinity to DNA as predicted by in silico alanine scanning37 
(Reproduced with permission) 
 
Mutagenesis studies suggested that the above residues may be 
involved in Gli1 binding to DNA (Figure 9a). We chose the K350A 
and K340A mutants, showing the highest and intermediate G of 
binding, respectively , to test their direct interaction with DNA. An 
electrophoretic mobility shift assay (EMSA) was performed using 
equal amounts of recombinant GST-Gli1ZF-WT or GST-Gli1ZF-
K350A or GST-Gli1ZF-K340A (Figure 10b) and a DNA probe 
containing Gli-responsive consensus DNA sequence or a mutated 
version unable to bind Gli1 (Figure 10b). Comparison with the strong 
DNA binding affinity of the recombinant GST-Gli1ZF-WT confirms 
that GST-Gli1ZF-K350A was unable to bind DNA, whereas GST-
Gli1ZF-K340A did it, albeit to a significantly lower extent (Figure 
10b). Notably, these results correlate with the impaired and 
intermediate transcriptional activity of Gli1ZF-K350A and Gli1ZF-
K340A mutants in cell-based assays, respectively (Figure 10a), and 
suggest that both K350 and K340 are involved in DNA binding and 
transcriptional activity, although with a different strength.  
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Figure 10 Effect of Gli1ZF mutants on Gli1-dependent transcriptional activation. (A) 
Luciferase assay was performed in HEK293T cells transfected with GliBS-Luc, pRL-
TK Renilla (normalization control), Flag- Gli1 WT or the indicated Flag-Gli1 
mutants. Data show the mean ± SD of three independent experiments. *P< 0.05; 
**P< 0.01 vs Gli1 WT. (B) Gli1/DNA binding. Double-stranded oligonucleotide 
containing the canonical GliBS sequence or mutated GliBS sequence used as control 
was used as probe (P) in EMSA experiments. The assay was performed using 
recombinant GST-Gli1ZF-WT (Gli1 zinc-finger fragment: aa 242–424), GST-Gli1ZF-
K350A, GST-Gli1ZF-K340A. Data are shown as a ratio of GST-Gli1ZF-WT or GST-
Gli1ZF mutants bound to the labeled GliBS probe/GliBS free probe normalized to the 
amount of GST-Gli1ZF-WT/DNA binding ± SD *P< 0.05 vs Gli1 WT. 
To correlate computational with experimental studies, a mutation 
assay was performed on HEK293T cells; these samples transiently 
express ectopic Gli1 or different Gli1 mutants, and a Gli-dependent 
luciferase reporter. The results obtained from such mutagenesis assays 
highlighted the role played by those residues in ZF4 and ZF5 domains 
in the transcriptional activity of Gli137 (Figure 10).  
 
 
 
A2.2 In Silico Screening: Gli1 Linkage to Natural Products 
 
Gli1
P
A B
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An in house library composed of about 1000 unique natural 
products is available in Prof. Bruno Botta’s laboratory, and it was the 
starting point to elucidate how Gli1 binding to DNA might be 
modulated by small molecules38. Literature data and results from the 
mutagenesis assays were used as source for a docking studies39. 
According to the setting of the docking analysis, only small molecules 
able to interact with at least one of the basic residues (ZF4, ZF5 ones) 
were selected34. The in silico screening identified six molecules (three 
vismiones, GlaB, chalcone V94 and the opioid alkaloid narceine) as 
potential Gli1 inhibitors37 (Figure 11). 
 
 
Figure 11 Structure of the six virtual hits. 
 
To assess the functional activity of these products as specific 
modulators of Gli1, we performed the Gli-dependent luciferase 
reporter assay on HEK293T cells (Figure 12).  
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Figure 12 Gli1-induced transcription in HEK293T cells, treated with increasing 
concentrations of different compounds or DMSO as control37 (Reproduced with 
permission). 
The results of biological assays highlighted for GlaB and 
Vismione E an inhibitory luciferase activity comparable to the 
GANT61 one, for Vismione B a partial inhibitory activity and other 
compound resulted not active37. Since the chemical instability of the 
vismione scaffold in different conditions, our studies were focused on 
GlaB and on its synthetic derivatives.  
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A3.1 The Importance of the Isoflavone Scaffold 
 
Isoflavones are a class of natural compounds mainly occurring in 
plants of the Leguminosae family, and possess natural roles in plants 
defense. In last decades, these compounds have received much 
attention due to their interesting biological activity and benefits to 
human health40, 41. Moreover, as highlighted by genistein and its 
derivatives, isoflavones have displayed noticeable pharmacophoric 
preference for Hh targets30. 
The isoflavone nucleus consists of two phenyl rings linked by a 
propane bridge to form an oxygenated heterocyclic ring, resulting in 
the typical 15 carbon atoms skeleton (C6-C3-C6) with three rings, 
labelled A, B and C (Figure 13). Isoflavonoids differ from flavonoid 
basic structure because B-ring attaches to C-3 instead of C-2. 
 
Figure 13 Isoflavones skeleton C6-C3-C6. 
 
Most of the isoflavones have been isolated from natural sources, 
but extraction methods furnish only very few amounts of pure 
samples. However, their simple structure features can be approached 
by convenient synthetic method. 
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A3.2 Computational Design of Isoflavones Targeting Smo or 
Gli 
 
By screening of a natural compounds library, GlaB, a prenylated 
isoflavone, was recentely identified by our research group as the first 
small molecule acting as direct inhibitor of Gli1/DNA interaction and 
endowed by a significant anticancer efficacy in vivo and in vitro 
against Hh-dependent MB and BCC. The mechanism of action of 
GlaB was largely studied at molecular leves, thus pointing to the 
druggability of Gli1/DNA interaction in the treatment of Hh-
dependent cancers. GlaB was considered as starting point to develop 
numerous derivatives. 
Previously, a number of GlaB synthetical derivatives possessing 
modifications on the ring B have been synthesized and tested as Hh 
inhibitors37, displaying no effects (DGB1-5, Figure 14). This data 
focused preliminary structure-activity relationships of GlaB, and led 
us to identify relevant molecular key factors for the inhibition of Gli1 
binding to DNA and related transcriptional activities. 
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Figure 14 DGB 1-5 derivatives. 
These evidences highlighted the pharmacophoric importance of 
the substitutions at the isoflavone’s ring B in binding to Gli1 and 
preventing its interaction to DNA.  
Here we designed a small-sized library of isoflavones bearing 
different substituents in different position of the ring B. 
These molecules (Table 1)42 were tested in silico to investigate 
the interaction with the heptahelical bundle of Smo or the DNA 
binding site of Gli1. The computational protocols already validated in 
previous works37, 43, 44, 45, 46, displayed that the O-substitutions at para 
position of ring B favoured the interaction with Smo, meanwhile the 
same substitutions at meta position preferred the Gli1 interaction. 
We observed these results through the analysis of the shape of the 
binding sites of Smo or Gli1: Smo possesses a narrow and elongated 
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binding site in the linear heptahelical bundle of the receptor, Gli1 has 
a marginally bended binding site at the interface between ZF4 and 
ZF5.  
Based on molecular modelling suggestions, we decided to design 
and synthesize the compounds reported in Table 1, to investigate their 
effects on the modulation of Hh signaling. 
 
 
Table 1 Chemical structure of isoflavone derivatives investigated in this work as Hh 
inhibitors42. 
 
Cmpd R1 R2 Cmpd R1 R2 
GlaB -OPrenyl -OPrenyl 12 -Op-BnCF3 -OCH3 
4c -OH -H 13 -OCH3 -Op-BnCF3 
5 -OPrenyl -OCH3 14 -Op-BnCF3 -H 
6 -OCH3 -OPrenyl 15 -OBn -OBn 
7 -OPrenyl -H 16 -Op-BnCN -OCH3 
8 -OBn -OCH3 17 -Op-BnCO2CH3 -OCH3 
9 -OCH3 -OBn 18 -Op-BnCO2NH3 -OCH3 
10 -OGeranyl -OCH3 19 -Op-BnNO2 -OCH3 
11 -OCH3 -OGeranyl    
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A3.3 Synthetic Strategy to Isoflavone Derivatives 
 
Since extraction methods developed allow us to get very limited 
amounts of pure isoflavone, several synthetic procedures used for the 
preparation of isoflavones have been developed47. 
Previously, we afforded a synthetic route for the total synthesis 
of isoflavones scaffold (and, in particular, of GlaB), featuring six-step 
with an overall yield of 7%48; that approach is based on a palladium 
catalyzed cross coupling reaction of 3-iodochromone with the 
corresponding boronic acid. This route affects with the impossibility 
to synthesize GlaB derivatives, due to the challenging mono-
functionalization of the two hydroxyl groups on ring B. This inspired 
us to mature a mild and cost effective method, inspired to the 
“deoxybenzoin route”49, which might enable the synthesis of 
isoflavones bearing different substituents on meta and para positions 
of ring B. This route foresees three simple steps. 
The first step of the route consists in a Friedel-Crafts acylation, 
in which 3,5-dimethoxyphenol was treated with suitable  phenyl acetic 
acids in presence of BF3·Et2O, used as Lewis acid; this step leads to 
the formation of the deoxybenzoin intermediate. Appropriate 
substituted phenyl acetic acids are necessary to achieve the synthesis 
of free meta- or para-hydroxyl groups on ring B. This step is followed 
by a Vilsmeier-Haak reaction, in presence of 
(chloromethylene)dimethyliminium chloride, that accomplishes the 
addition of one carbon atom and the cyclization of deoxybenzoin, 
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affording the formation of the isoflavone scaffoild (Scheme 1). The 
last step is represented by a reaction of functionalization of the 
isoflavone ring B, and was performed using an alkyl or aryl bromide 
and K2CO3 in refluxing acetone. This route (with an overall yield of 
around 15%), achieved the preparation of a small library of GlaB-ring 
B derivatives meta- or para- substituted, ready to be tested against the 
Hh pathway. 
 
 
Scheme 1 Deoxybenzoin approach: i) BF3·OEt2, 90 °C, 90 min 50-60%; ii) BF3·OEt2, 
(chloromethylene)dimethyliminium chloride, DMF, rt, 2 h 28-32%; iii) alkyl- or 
benzyl- bromide, K2CO3, acetone, 45 °C, 17 h, 88-95%. 
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A3.4 Biological Evaluation of Isoflavones Derivatives 
 
A3.4.1 Hh inhibition by Isoflavones Derivatives 
 
Biological investigation of newly isoflavones were performed in 
a luciferase report assay using, the NIH3T3 Shh-Light II as sample 
cells (which incorporate Gli-responsive firefly luciferase reporter) and 
the pRL-TK Renilla as normalization control. The procedure adopted 
to investigate the ability of the new isoflavones to inhibit Hh signaling 
provided the treatment of the cells with a synthetic Smo antagonist 
(SAG) alone, or in combination with selected molecules45. 
We observed two different behaviors according to the meta- and 
the para-position substitutions on the B ring: 
 meta substitutions: compounds 4c, 14, 16, 17, 18 and 19 
exhibited mild activity at the concentration of 30 μM; 5, 
8, 10 and 12 displayed high activity, with a range of IC50 
between 2 and 4 μM; 7 was inactive (Figures 15 and 16a, 
Table 2); 
 para substitutions: compounds 13 and 15 exhibited high 
activity as Hh inhibitors with an IC50 of 3.4 μM for the 
first and 0.29 μM for the latter; 6 and 9 showed mild 
activity and 11, in the end, evidenced to be toxic45 (Figure 
16b and Table 2). 
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Figure 15 Hh inhibition by isoflavones 4c, 7, 14, 16, 17, 18, and 19. Dose-response 
curve of compounds with a substituent at –meta position of ring B in SAG-treated 
NIH3T3 Shh-Light II cells. Treatment time was 48 h, and normalization was against 
Renilla luciferase. Data show the mean ± SD of three independent experiments: (*) P 
< 0.05 vs SAG. 
 
 
Figure 16 Hh inhibition by isoflavones 5, 6, 8, 9, 10, 12, 13, 15. Dose-response curve 
of compounds with a substituent at meta (A) or at para (B) position of ring B in SAG-
treated NIH3T3 Shh-Light II cells. Treatment time was 48 h, and normalization was 
against Renilla luciferase. Data show the mean ± SD of three independent 
experiments: (*) P < 0.05 vs SAG; (**) P < 0.01 vs SAG. 
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Table 2 IC50 values for new isoflavone derivatives selected in the Shh-Light II cells 
and in MEFs assay. 
Substitution at meta position 
 Shh-Light II IC50 (μM) MEFs IC50 (μM) 
5  2.87±0.33 5.695±0.84 
8  3.719±0.88 17.12±0.87 
10 3.61±0.31 21.22±1.21 
12 2.58±0.12 11.50±0.85 
16  16±1.1 / 
17 > 30 / 
18  > 30 / 
19 > 30 / 
4c > 30 / 
7 > 30 > 20 
14 10.47±0.73 26.73±1.7 
Substitution at para position 
 Shh-Light II IC50 (μM) MEFs IC50 (μM) 
6 6.97±0.67 10.7±1.01 
9 6.921±0.76 39.2±2.03 
11 nd nd 
13 3.477±0.66 55.29±2.57 
15 0.29±0.12 57.74±3.98 
 
The structure of the most effective derivatives are summarized in 
figure 17. 
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Figure 17 Structure of the most effective synthetic derivatives meta- (on the left) and 
para- substituted. 
 
A3.5 Smo and Gli1 Antagonists 
 
To explore the activity of the most powerful molecules as Gli1 or 
Smo modulators, we performed the Gli1-dependent luciferase reporter 
screening assay, in which increasing amount of selected molecules 
were incubated with mouse embryonic fibroblasts (MEFs) expressing 
ectopic Gli1. To validate the assay method, the FDA approved 
molecule Vismodegib (GDC-0449) was used as control (Figure 18). 
As showed in figure 17a, compounds 5 and 12 are the most promising 
Gli1 activity inhibitors, with IC50 values between 5 and 11 μM, while 
Vismodegib exhibited no effect on Gli1 transcriptional activity. These 
results are in agreement with computational and experimental studies. 
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Figure 18 Specificity of Smo and Gli1 antagonists. 
The preliminary results that emphasized the Gli1 inhibition 
efforded by 5 and 12 derivatives, were confirmed in Smo-/- MEFs 
transfected with ectopic Gli (Figure 19).  
Compounds 5 and 12 inhibited the luciferase activity Gli-
responsive elements (Figure 18a), while compound 13 and 15 did not 
showed activity (Figure 18b). Moreover, to demonstrate that 5 and 12 
operate downstream of Smo, these molecules were tested in SuFu-/- 
MEFs cells, featured by constitutive activation of the Hh pathway due 
to the loss of the negative regulator SuFu. Compounds 5 and 12 
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critically reduced the expression of Gli1 and Gli2, the final effectors 
of Hh pathway; on the other side, compounds 13 and 15 showed no 
activity.  
 
 
Figure 19 Specificity of Smo and Gli antagonists. 
 
The results obtained from these biological assays confirm the 
computational modeling predictions, evidencing that isoflavones with 
a para-substituent on the B ring act on upstream receptor Smo, instead 
those presenting meta-substitutions target the downstream effectors 
Gli. 
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A3.6 Binding Sites of Smo and Gli1 Antagonists: Docking 
Analysis of the New Isoflavone Derivatives 
 
The possible binding mode of the most promising Hh inhibitors 
towards Smo or Gli1 crystallographic structure was evaluated thanks 
to molecular modeling simulations. Noteworthy, our research group 
was able to predict the binding mode of Gli134 and Smo antagonists49, 
50 using established computational protocols, which were used to dock 
compounds 5 and 12 towards Gli1ZF domain, and molecules 13 and 
15 whithin the heptahelical bundle of Smo.  
 Gli1 antagonists evaluation (5 and 12 derivatives) 
Molecular docking of Gli1ZF/antagonists highlighted a 
comparable binding mode of the two molecules 5 and 12, with the 
isoflavone core occupying a surface region at the interface between 
ZF4 and ZF5 (Figure 20). The interactions established are comparable 
to the ones already observed for GlaB34, even if the isoflavone core is 
established in a different manner: the isoflavone core of the new 
synthetic molecules interacts with the K350 through H-bond, 
previously highlighted by mutagenesis studies as a crucial center for 
Gli1 transcriptional activity34, and with T355, K360 and H351. The 
ring B of the isoflavone is docked in a model that hides the nuclear 
localization system (NLS) at level of the residue T374 to the solvent 
area. The isoprenyl group present in 5 is docked in a groove near S357 
and N358 residues (figure 20a), while the aromatic portion of 12 is 
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oriented towards the ZF5, with which establishes 
stackinginteraction with the residue T373 (Figure 20b). 
 
 
Figure 20 Predicted binding mode of Gli1 antagonists. The docking pose of 5 (A) and 
12 (B) is shown as yellow sticks. Gli1ZF is shown as green cartoon. Residues within 
5 Å from the ligands are showed as lines. Residues H-bonded or stacked to the ligands 
are showed as sticks, and are labeled. Residues numbers correspond to the full length 
human Gli1. H-bonds are showed as magenta dashed lines, Zn(II) ions as grey 
spheres. 
 Smo antagonists evaluation (13 and 15) 
Synthetic molecules 13 and 15 adapt in the lipophilic site present 
in the heptahelical bundle of the receptor. Indeed, the isoflavone core 
of the Smo antagonists binds in two conformations, which are most 
likely biased by compared to the single substitutions at para position 
on the ring B of 13, and is in part due to the presence of two aryl 
substituents on the B ring of 15 (Figure 21). Isoflavone core of 13 
binds a Smo region generally occupied by multiple antagonists, as 
confirmed by X-ray crystallography,46, 50, 51, 52, 53 and establishes: H-
bonds with R400, both H-bonds and interactions with T394 and 
stacking interactions with F484 (Figure 21a). The lipophilic 
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portions are docked in the intramembrane region of the receptor52, 54, 
while the trifluoromethyl moiety is near the entrance of the binding 
site, corresponding to the extracellular portion of Smo. In the case of 
15, in which B ring is substituted by two hydrophobic benzyloxy 
groups, the isoflavone core binds the extracellular portion of Smo in 
an opposite site than to 13; in fact, the two hydrophobic substituents 
are projected in the heptahelical bundle of Smo, near  to non-polar 
residues F222, M230, W281, F391, H470, L515 and L522. Among all 
the aminoacids present in the heptahelical bundle of Smo, H470 
established interactions with the benzyl moieties present in the 
molecule 15 (Figure 21b). 
 
Figure 21 Predicted binding mode of Smo antagonists. The docking pose of 13 (A) 
and 15 (B) is shown as yellow sticks. Smo is shown as green cartoon. Residues within 
5 Å from the ligands are showed as lines. Residues H-bonded or stacked to the ligands 
are showed as sticks, and are labeled. Residues numbers correspond to the full length 
human Smo. H-bonds are showed as magenta dashed lines. 
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A3.7 Smo and Gli Antagonists: a Smart Combination in 
Anticancer Treatment 
 
Hh pathway aberrant activation is a crucial issue in 
tumorigenesis, and in the last decade the design of Hh inhibitors is 
giving rise to increasing interest in drug discovery. With the aim to 
overcome complications due to the resistance phenomena, we decided 
to combine two isoflavones targeting Smo or Gli1, respectively, and 
to investigate their potential synergistic affect.  
We analyzed the ability to inhibit Hh-dependent tumor growth in 
primary MB cells freshly isolated form Ptch ± mice tumors, and tested 
in short-term cultures to maintain Hh sensitivity in vitro. The new 
synthetic isoflavones exhibited an inhibitory cell growth with 
comparable efficiency to the GlaB, used as reference (Table 3 and 
Figure 22). 
 
Table 3 Percentage of growth inhibition in primary MB cells freshly isolated from 
Ptch+/- mice, after 72 h of incubation with the Gli1 selected antagonists. 
 
 
[μM] GlaB 5 12 13 15 
0.125  28.6±2.7 5.9±3 37.7±3.1 20.8±5.3 33.3±3.8 
0.25  42.4±3.1 26.3±4 40.6±2.3 23.5±3.1 44.2±4.9 
0.5  46.6±3.4 29.2±3.6 44.52±3.6 32.5±1.3 51.4±5.1 
1  55.9±4 35.6±2.1 50.9±4.8 51.8±3.5 61.2±4.8 
5  65.1±5.3 55.4±5 54±5 54.2±4.4 66.6±4.1 
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Figure 22 Inhibition of Hh-dependent tumor growth. Primary MB cells were freshly 
isolated from Ptch1+/- mice tumor and treated with a Smo- or a Gli1- antagonist, at 
the indicated concentration, or with DMSO only, as control. After the indicated times, 
a trypan blue count was performed to determine the growth rate of viable cells. In all 
experiments data show the mean ± SD of three independent experiments: (*) P < 0.01 
vs CTR (DMSO). 
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Remarkably, the combination between a Gli1 (5, 12 and GlaB) 
and a Smo (13 or 15) antagonist reduced cells proliferation at striking 
lower concentrations (Table 4 and Figure 22). In fact, GlaB afforded 
a 46% growth inhibition (Table 3) at the concentration of 0.5 µM, 
meanwhile the combination of 12 and 13 afforded a comparable 
inhibition at the final concentration 0.125 µM (Table 4). 
 
Table 4 Percentage of growth inhibition in primary MB cells freshly isolated from 
Ptch+/- mice, after 72 h of incubation with the binary combination between a Gli1- 
and a Smo- antagonist. 
 
The combination of GlaB with isoflavone 13 or derivative 15 bear 
53% and 63.4% Hh-dependent tumor growth inhibition at the 
concentration of 0.25 µM, respectively. The best result was 
accomplished with the binary administration of GlaB and 15: a 70% 
cell growth inhibition at the concentration of 0.5 µM (Table 4 and 
Figure 23). 
[μM] 12 + 13 12 + 15 5 + 13 5 + 15 GlaB + 13 GlaB + 15 
0.125 44.2±2.7 35.5±5 31.8±2.7 32.0±4.6 33.5±1.1 38.3±4.7 
0.25 50.1±2.9 50±3.7 33±2 34±2.1 53.1±2.5 63.4±3.1 
0.5 53.5±3.9 55.2±4.6 35±3.3 40±3.6 60.1±1.6 70±4.2 
1 61.9±3.4 67.9±3.8 45.7±3 51.9±2.7   
2 58.6±4 68.2±1.3 47.1±1.5 60.4±1.5   
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Figure 23 Synergistic combination of isoflavone Smo and Gli antagonists. Primary 
MB cells were freshly isolated from Ptch1+/- mice tumor and treated with the binary 
combination between a Smo- and a Gli1- antagonist, at the indicated concentration. 
DMSO was used as control. After the indicated times, a trypan blue count was 
performed to determine the growth rate of viable cells. In all experiments data show 
the mean ± SD of three independent experiments: (*) P < 0.01 vs CTR (DMSO). 
 
A3.8 Conclusions 
 
A new synthetic route leads us to obtain new isoflavone 
derivatives, and these were tested in vitro. Here, we reported a number 
of isoflavones able to interact especially with Smo receptor or the Gli 
protein; experimental results displayed that isoflavones with meta 
substitutions on B ring binds preferrentially Gli1ZF domain, 
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meanwhile the para substituted derivates bind the Smo receptor. 
These results are in agreement with molecular modeling studies. 
Furthermore, we observed that the co-admistration of a Smo and 
a Gli antagonist afforded similar Hh inhibition effects with individual 
doses of compounds 12 and 13 decreased by four time at sub-molar 
concentrations; the most powerful effect was obtained when GlaB was 
combined with compound 15. 
In conclusions, our results highlighted that targeting Hh pathway 
at both upstream and downstream levels, using a Smo inhibitor and a 
Gli1 antagonist, efficiently improve Hh inhibition at lower individual 
molecules doses. 
We expect that our study could trigger more investigations on 
clinically highlighting Hh inhibitors, and support the treatment of Hh-
dependent tumors with a combination therapy. 
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A3.9 General Methods for Sapienza project 
 
All non-aqueous reactions were performed under an argon 
atmosphere using flame-dried glassware and standard syringe/septa 
techniques.  
All absolute solvents were purchased as anhydrous grade from 
Sigma Aldrich and used without further purification unless otherwise 
stated. Solvents for extractions, flash column chromatography (FC) 
and thin layer chromatography (TLC) were purchased as commercial 
grade from Sigma Aldrich and used without further purification unless 
otherwise stated. Reactions were magnetically stirred and monitored 
by TLC performed on Merck TLC aluminum sheets (silica gel 60 
F254). Spots were visualized with UV light (λ = 254 nm). 
Chromatographic purification of products (FC) was performed using 
Sigma Aldrich silica gel 60 for preparative column chromatography 
(particle size 40-63 μm). 
Melting points (Mp) were obtained in open capillary tubes using 
a Büchi melting point apparatus B-545 and are uncorrected. 
1H- and 13C-NMR spectra were recorded in CDCl3, acetone-d6, 
DMSO-d6 or methanol-d4 on a Bruker AV-400 400 MHz spectrometer 
(operating at 400 MHz for 1H and 100 MHz for 13C) at room 
temperature and tetramethylsilane (TMS) as internal standard. 
Chemical shifts (δ) are reported in parts per million (ppm) and are 
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referenced to CDCl3 (δ = 7.26 ppm for 1H, δ = 77.16 ppm for 13C), 
acetone-d6 (δ = 2.05 ppm for 1H, δ = 29.84 ppm for 13C) DMSO-d6 (δ 
= 2.50 ppm for 1H, δ 39.52 ppm for 13C), or MeOH-d4 (δ = 3.31 ppm 
for 1H, δ 49.00 ppm for 13C). All 13C-NMR spectra were measured 
with complete proton decoupling. Data for NMR spectra are reported 
as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad signal, J = coupling constant in Hz. 
High-resolution mass spectra (HRMS) were recorded on 
Bruker BioApex Fourier transform ion cyclotron resonance (FT-ICR) 
mass spectrometer. 
HPLC analysis were performed on a Waters 2690 Separation 
Module, equipped with a Rheodyne Model 8125 20-µL injector and a 
Model M486 programmable multi-wavelength detector (PDA). 
Chromatographic data were collected and processed using the 
Empower Chromatography Manager software. Column: Phenomenex 
Luna C18, 5 µm (250 × 4.6 mm); eluent A) H2O/CH3CN, 95:5 v/v, 
eluent B) H2O/CH3CN, 5:95 v/v; gradient elution: for 0-5 min A:B = 
50:50; 5-20 min up to 100% B; 20-25 min to 100% B; Flow rate: 1.0 
ml/min; UV detection at 295 nm. The purity of the compounds was 
always higher than 95 %. 
The compounds are referred to by increasing numbers X, 
following the sequential references in the main text. 
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A3.10 Total Synthesis of GlaB and GlaB Ring-B Derivatives 
 
A3.10.1 General procedure for the preparation of 
deoxybenzoines 
 
In a two-neck round-bottom flask a mixture of 3,5-
dimethoxyphenol (6 mmol, 1.00 equiv.), 3,4-disubstituted-
phenylacetic acid (6 mmol, 1.00 equiv.) and BF3∙Et2O (48 mmol, 8.00 
equiv.) was stirred at 90 °C for 90 min under argon. The reaction 
mixture was poured into 10% aqueous NaOAc (100 mL) and allowed 
to stir at room temperature for 24 h, forming a brown precipitate. The 
precipitate was filtered and washed with H2O (2 x 20 mL). The 
precipitate was resuspended with EtOAc, dried over Na2SO4 and 
finally concentrated in vacuo. The residue was purified by FC using a 
mixture of Petroleum Ether/EtOAc as eluent, to obtain the 
corresponding deoxybenzoin. 
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1-(2-hydroxy-4,6-dimethoxyphenyl)-2-(3-hydroxy-4-
methoxyphenyl)ethanone (3a) 
 
 
 
Pale Yellow solid (Yield 55%); mp: 114.2-115.3 °C; TLC (Petroleum 
Ether/EtOAc, 7:3 v/v): Rf= 0.33. 
 
1H NMR (400 MHz, (CD3)2CO): δH 13.88 (s, 1H, C2-OH), 7.51 (brs, 
1H, OH), 6.84 (d, J = 8.4 Hz, 1H, H-5’), 6.76 (d, J = 2.4Hz, 1H, H-
2’), 6.67 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H, H-6’), 6.06 (d, J = 2.0 Hz, 
1H, H-5), 6.04 (d, J = 2.4 Hz, 1H, H-3), 4.20 (s, 2H, CH2), 3.93 (s, 3H, 
OCH3), 3.84 (s, 3H, OCH3), 3.80 (s, 3H, OCH3); 13C NMR (100 MHz, 
(CD3)2CO): δC 204.18, 168.70, 167.40, 163.76, 147.22, 147.10, 
129.51, 121.34, 117.29, 112.25, 106.10, 94.56, 91.47, 56.23, 56.19, 
56.04, 50.00; HRMS (m/z): [M+H]+ calcd. for C17H19O6, 319.11761; 
found, 319.11767.  
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2-(4-hydroxy-3-methoxyphenyl)-1-(2-hydroxy-4,6-
dimethoxyphenyl)ethanone (3b) 
 
 
 
Pale Yellow solid (Yield  55%); mp: 133-135 °C; TLC (Petroleum 
Ether/EtOAc, 7:3 v/v): Rf = 0.33. 
 
1H NMR (400 MHz, (CD3)2CO): δH 13.87 (s, 1H, C2-OH), 7.42 (brs, 
1H, OH), 6.86 (d, J = 1.6 Hz, 1H, H-2’), 6.74 (d, J = 8.0 Hz, 1H, H-
5’), 6.69 (dd, J = 8.0 Hz , J = 1.6 Hz, 1H, H-6’), 6.07 (d, J = 2,4 Hz, 
1H, H-5), 6.05 (d J = 2,4 Hz, 1H, H-3), 4.23 (s, 2H, CH2), 3.95 (s, 3H, 
OCH3), 3.84 (s, 3H, OCH3), 3.81 (s, 3H, OCH3); 13C NMR (100 MHz, 
(CD3)2CO): δC 203.38, 167.79, 166.50, 162.89, 147.21, 145.29, 
126.95, 122.07, 114.65, 113.18, 105.25, 93.70, 90.59, 55.32, 55.16, 
49.32; HRMS (m/z): [M+H]+ calcd. for C17H19O6, 319.11761; found, 
319.11794. 
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1-(2-hydroxy-4,6-dimethoxyphenyl)-2-(3-hydroxyphenyl) 
ethanone (3c) 
 
 
 
Pale Orange solid (Yield 60%). Mp: 103.5-105 °C. TLC Rf = 0.30 
(EtOAc/PE 2:3, UV).  
 
1H-NMR (400 MHz, acetone-d6): δH 13.85 (s, 1H, OH), 8.22 (brs, 1H, 
OH), 7.12 (t, J= 8.0 Hz, 1H, H-5’), 6.75-6.73 (m, J= 1.6 Hz, 1H, H-
2’), 6.71-6.70 (m, 1H, H-4’), 6.68 (dd, J= 8.0, J= 2.4 Hz, 1H, H-6’), 
6.06 (d, J = 2.0 Hz, 1H, H-5), 6.05 (d, J = 2.0 Hz, 1H, H-3), 4.25 (s, 
2H, CH2), 3.92 (s, 3H, OCH3), 3.85 (s, 3H, OCH3). 13C-NMR (100 
MHz, acetone-d6): δC 203.82, 168.72, 167.51, 163.81, 138.24, 129.99, 
121.54, 117.20, 114,23, 94.61, 91.52, 56.19, 56.07, 50.64. HRMS 
(ESI): calcd. for C16H17O5 [(M+H)+]: 289.10705; found, 289.10683. 
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2-(3,4-dihydroxyphenyl)-1-(2-hydroxy-4,6-
dimethoxyphenyl)ethanone (3d) 
 
 
 
Pale Brown solid (Yield 50%); mp: 130-132 °C; TLC (Petroleum 
Ether/EtOAc, 7:3 v/v): Rf = 0.30. 
 
 1H NMR (400 MHz, (CD3)2CO): δH 13.90 (s, 1H, C2-OH), 7.76 (brs, 
2H, OH), 6.75-6.73 (m, 2H, H-2’ and H-5’), 6.58 (dd, J = 8.0 Hz, J = 
1.2 Hz, 1H, H-6’), 6.06 (d, J = 2.0 Hz, 1H, H-5), 6.04 (d, J = 2.8 Hz, 
1H, H-3), 4.16 (s, 2H, CH2), 3.93 (s, 3H, OCH3), 3.84 (s, 3H, OCH3). 
13C NMR (100 MHz, (CD3)2CO): δC 204.34, 168.71, 167.37, 163.74, 
145.64, 144.58, 128.15, 121.77, 117.38, 115.84, 106.08, 94.55, 91.45, 
56.17, 56.03, 49.99; HRMS (m/z): [M+H]+ calcd. for C16H17O6, 
305.10196; found, 305.10178.   
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A3.10.2 General Procedure for the Vilsmeier-Haack 
Reaction for the Preparation of Isoflavones 
 
In a two-neck round-bottom flask a solution of deoxybenzoin (3 
mmol, 1.00 equiv.) in DMF (5 mL) was cooled to 0 °C and BF3·Et2O 
(9 mmol, 3.00 equiv.) was added drop wise under argon. In another 
flask, DMF (8 mL) was cooled to 0 °C and PCl5 (4.5 mmol, 1.50 
equiv.) was added. The mixture was then allowed to stir at 55 °C for 
20 min. The light yellow colored solution containing N,N’-
dimethyl(chloromethylene)ammonium chloride was then added to the 
above reaction mixture at 0 °C. The mixture was stirred at room 
temperature for 2 h under argon and then poured into 0.1 N methanolic 
HCl (70 mL) and allowed to stir at 70 °C for 2 h. After removing the 
solvents in vacuo, H2O (50 mL) and EtOAc (50 mL) were added and 
the aqueous phase was extracted with EtOAc (3 x 100 mL). The 
combined organic layers were washed once with brine (100 mL), dried 
over Na2SO4, and finally concentrated under reduced pressure. The 
residue was purified by FC using Petroleum Ether/EtOAc as eluent, to 
give the corresponding isoflavone. 
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3-(3-hydroxy-4-methoxyphenyl)-5,7-dimethoxy-4H-chromen-4-one 
(4a) 
 
 
 
Brown solid (Yield 32%); mp: 175-177 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.35. 
 
1H NMR (400 MHz, (CD3)2SO): δH 8.97 (s, 1H, OH), 8.14 (s, 1H, H-
2), 6.98 (d, J = 2.0 Hz, 1H, H-2’), 6.93 (d, J = 8.0 Hz, 1H, H-5’), 6.87 
(dd, J = 8.0 Hz, J = 2 Hz, 1H, H-6’), 6.65 (d, J = 2.0 Hz, 1H, H-6), 
6.50 (d, J = 2.4 Hz, 1H, H-8), 3.88 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 
3.78 (s, 3H, OCH3); 13C NMR (100 MHz, (CD3)2SO): δC 173.69, 
163.56, 160.80, 159.15, 150.89, 147.40, 145.92, 145.78, 124.79, 
119.78, 116.63, 116.54, 111.81, 108.97, 96.17, 92.91, 56.12,  55.94, 
55.63; HRMS (m/z): [M+H]+ calcd. for C18H17O6, 329.10196; found, 
329.10203. 
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3-(4-hydroxy-3-methoxyphenyl)-5,7-dimethoxy-4H-chromen-4-
one (4b) 
 
 
 
Brown Solid (Yield 31%); mp: 223-224 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.29. 
 
1H NMR (400 MHz, CDCl3): δH 7.77 (s, 1H, H-2), 7.28 (s, 1H, H-2’), 
6.91 (d, J = 8.0 Hz,1H, H-5’), 6.87 (d, J = 8.0 Hz, 1H, H-6’), 6.44 (brd, 
1H, H-6), 6.37 (brd, 1H, H-8), 5.80 (s, 1H, OH), 3.93 (s, 3H, OCH3), 
3.90 (s, 3H, OCH3), 3.88 (s, 3H, OCH3); 13C NMR (100 MHz, 
CDCl3): δC 175,58, 164.00, 161.58, ,160.00, 150.32, 146.29, 145.81, 
126.13, 124.26, 121.68, 114.23, 112.65, 110.02, 96.30, 92.65, 56.51, 
56.19, 55.85; HRMS (m/z): [M+H]+ calcd. for C16H17O6, 329.10196; 
found, 329.10171. 
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3-(3-hydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one (4c) 
 
 
Brown Solid (Yield 28%); mp: 194.8-196.7 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.30. 
 
1H NMR (400 MHz, (CD3)2SO): δH 9.43 (s, 1H, OH), 8.20 (s, 1H, H-
2), 7.18 (t, J = 8.0 Hz, 1H, H-5’), 6.92 (s, 1H, H-2’), 6.88 (d, J = 8.0 
Hz, 1H, H-4’), 6.75 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H, H-6’), 6.67 (d, J 
= 2.0 Hz, 1H, H-6), 6.52 (d, J = 2.0 Hz, 1H, H-8), 3.88 (s, 3H, OCH3), 
3.83 (s, 3H, OCH3); 13C NMR (100 MHz, (CD3)2SO): δC 173.50, 
163.66, 160.83, 159.17, 156.96, 151.50, 133.39, 128.96, 125.08, 
119.64, 116.22, 114.62, 108.98, 96.27, 92.99, 56.16, 55.99; HRMS 
(m/z): [M+Na]+ calcd. for C17H14O5Na, 321.07334; found, 321.07312. 
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3-(3,4-dihydroxyphenyl)-5,7-dimethoxy-4H-chromen-4-one (4d) 
 
 
 
White solid (Yield 30%), Mp: 127–129°C. 
 
1H-NMR (400 MHz, methanol-d4): δ = 7.86 (s, 1H, H-2), 6.88 (brs, 
1H, H-2′), 6.70 (brs, 2H, H-5′ and H-6′), 6.50 (d, J = 2.0 Hz, 1H, H-
6), 6.40 (d, J = 2.0 Hz, 1H, H-8), 3.80 (s, 3H, OCH3), 3.79 (s, 3H, 
OCH3). 13C-NMR (100 MHz, methanol-d4): 175.0, 165.1, 161.1, 
159.9, 151.3, 145.1, 145.0, 126.5, 123.1, 120.5, 117.0, 110.0, 114.5, 
95.9, 92.8, 55.1. HRMS (ESI): calcd. for C17H15O6 [(M+H)+]: 
315.086300; found, 315.086363. 
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A3.10.3 General Procedure for the Alkylation/Benzylation 
Reaction 
 
To a solution of the isoflavone (0.18 mmol, 1.00 equiv.) in 
acetone (5 mL), K2CO3 (1.8 mmol, 10.00 equiv.) was added. After 
stirring for 15 min the corresponding alky/benzyl bromide (0.9 mmol, 
5.00 equiv.) was added dropwise to the mixture and stirred at 45 °C 
overnight. After removing the acetone in vacuo, H2O (10 mL) and 
EtOAc (20 mL) were added and the aqueous phase was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were dried over 
Na2SO4, and finally concentrated under reduced pressure. The residue 
was purified by FC using Petroleum Ether/EtOAc as eluent to give the 
corresponding substituted-isoflavone. 
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Glabrescione B (XIII) 
 
 
 
White solid (Yield 90%). Mp: 102–104°C. 
 
1H-NMR (400 MHz, acetone-d6): δ = 7.94 (s, 1H, H-8), 7.16 (d, J = 
1.6 Hz, 1H, H-15), 6.99 (dd, J = 8.0 Hz and 1.6 Hz, 1H, H-11), 6.89 
(d, J = 8.0 Hz, 1H, H-12), 6.50 (d, J = 2.0 Hz, 1H, H-1), 6.42 (d, J = 
2.0 Hz, 1H, H-3), 5.43 (m, 2H, 2 x =CH), 4.51 (d, J = 6.8 Hz, 4H, 
OCH2), 3.86 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 1.70 (s, 6H, 2 CH3), 
1.67 (s, 6H, 2 CH3). 13C-NMR (400 MHz, CDCl3): δ = 175.6, 164.0, 
161.2, 159.7, 150.2, 148.9, 148.5, 136.9, 126.5, 125.0, 121.4, 120.7, 
115.5, 110.0, 114.0, 96.5, 92.6, 66.0, 56.4, 55.9, 25.6, 18.1. HRMS 
(ESI): calcd. for C27H31O6 [(M+H)+]: 451.211500; found, 451.211495. 
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5,7-dimethoxy-3-(4-methoxy-3-((3-methylbut-2-en-1-
yl)oxy)phenyl)-4H-chromen-4-one (5) 
 
 
White Solid (Yield 95%); Mp: 113-113.2 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.33. 
 
1H NMR (400 MHz, CDCl3): δH 7.76 (s, 1H, H-2), 7.22 (d, J = 2.0 Hz, 
1H, H-2’), 7.01 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H, H-6’), 6.88 (d, J = 8.0 
Hz, 1H, H-5’), 6.44 (d, J = 1.2 Hz, 1H, H-6), 6.37 (d, J = 2.4 Hz, 1H, 
H-8), 5.55 (t, J = 6.8 Hz, 1H, CH), 4.59 (d, J = 8.0 Hz, 2H, CH2), 3.94 
(s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 1.76 (s, 3H, 
CH3), 1.71 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3): δC 175.49, 
163.97, 161.59, 159.98, 150.28, 149.49, 148.03, 137.80, 126.14, 
124.78, 121.45, 120.00, 114.61, 111.20, 110.07, 96.29, 92.64, 65.93, 
56.51, 56.02, 55.84, 25.99, 18.38; HRMS (m/z): [M+H]+ calcd. for 
C23H25O6, 397.16456; found, 397.16441. 
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5,7-dimethoxy-3-(3-methoxy-4-((3-methylbut-2-en-1-
yl)oxy)phenyl)-4H-chromen-4-one (6) 
 
 
White Solid (Yield 95%); mp: 130.9-132.6 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.36. 
 
1H NMR (400 MHz, CDCl3): δH 7.77 (s, 1H, H-2), 7.23 (s, 1H, H-2’), 
6.95 (dd, J  = 8.0 Hz, J = 2.0 Hz, 1H, H-6’), 6.87 (d, J = 8.0 Hz, 1H, 
H-5’), 6.43 (d, J = 1.6 Hz, 1H, H-6), 6.36 (d, J = 1.6 Hz, 1H, H-8), 
5.52 (t, J = 6.4 Hz, 1H, CH), 4.59 (d, J = 7.8 Hz, 1H, CH2), 3.93 (s, 
3H, OCH3), 3.89 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 1.76 (s, 3H, CH3), 
1.72 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3): δC 175.64, 163.96, 
161.59, 159.96, 150.30, 149.12, 148.29, 137.63, 126.11, 124.94, 
121.12, 120.14, 113.18, 112.84, 110.06, 96.28, 92.64, 65.86, 56.50, 
56.11, 55.83, 25.93, 18.34; HRMS (m/z): [M+H]+ calcd. for 
C25H20F3O5, 457.12573; found, 457.12543. 
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5,7-dimethoxy-3-(3-((3-methylbut-2-en-1-yl)oxy)phenyl)-4H-
chromen-4-one (7) 
 
 
 
Yellow Oil (Yield 95%); TLC (Petroleum Ether/EtOAc, 2:3 v/v): Rf 
= 0.31.  
 
1H NMR (400 MHz, CDCl3): δH 7.79 (s, 1H, H-2), 7.29 (t, J = 7.6 Hz, 
1H, H-5’), 7.16 (d, J = 2.0 Hz, 1H, H-2’), 7.08 (d, J = 8.0 Hz, 1H, H-
4’), 6.92 (dd, J = 8.0 Hz, J = 1.2 Hz, 1H, H-6’), 6.45 (d, J = 2.0 Hz, 
1H, H-6), 6.37 (d, J = 2.0 Hz, 1H, H-8), 5.51 (t, J = 6.8 Hz, 1H, CH), 
4.53 (d, J = 6.8 Hz, 1H, CH2), 3.94 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 
1.79 (s, 3H, CH3), 1.74 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3): 
δC 175.21, 164.05, 161.64, 159.99, 158.85, 150.78, 138.27, 133.51, 
129.23, 126.41, 121.61, 119.85, 115.38, 114.92, 110.14, 96.38, 92.68, 
64.95, 56.51, 55.87, 29.84, 25.99, 18.35; HRMS (m/z): [M+H]+ calcd. 
for C22H23O5, 367.15400; found, 367.15362. 
  
  72 
3-(3-(benzyloxy)-4-methoxyphenyl)-5,7-dimethoxy-4H-chromen-
4-one (8) 
 
 
 
Light Brown Solid (Yield 95%); mp: 128-129 °C TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.36. 
 
1H NMR (400 MHz, CDCl3): δH 7.45 (s, 1H, H-2), 7.37-7.26 (m, 3H, 
H-3”,H-4” and H-5”), 7.06 (d, J = 8.0 Hz, 1H, H-6”), 6.91 (d, J = 8.0 
Hz, 1H, H-2”), 6.44 (brd, 1H, H-6), 6.37 (brd, 1H, H-8), 5.17 (s, 2H, 
CH2), 3.95 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.89 (s, 3H, OCH3); 13C 
NMR (100 MHz, CDCl3): δC 175.59, 164.01, 159.99, 150.35, 148.01, 
137.32, 128.60, 127.90, 127.68, 124.87, 122.14, 115.58, 111.75, 
96.35, 92.69, 71.27, 56.61, 56.21, 55.90; HRMS (m/z): [M+H]+ calcd. 
for C25H23O6, 419.15891; found, 419.14871.  
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3-(4-(benzyloxy)-3-methoxyphenyl)-5,7-dimethoxy-4H-chromen-
4-one (9) 
 
 
 
Pale White solid (Yeld 95%); mp: 148.5-149 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.28. 
 
1H NMR (400 MHz, CDCl3): δH 7.75 (s, 1H, H-2), 7.43 (d, J = 8.0 Hz, 
2H, H-2”, H-6”), 7.35 (t, J = 8.0 Hz, 1H, H-3”, H-5”), 7.29 (d, J = 7.2 
Hz, 1H, H-4”), 7.25 (s, 1H, H-2’), 6.89 (d, J = 8.0 Hz, 1H, H-6), 6.86 
(d, J = 8.0 Hz, 1H, H-8), 6.42 (brd, 1H, H-6), 6.36 (brd, 1H, H-8), 5.17 
(s, 2H, CH2), 3.93 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 3.87 (s, 3H, 
OCH3); 13C NMR (100 MHz, CDCl3): δC 175.48, 164.00, 161.61, 
159.98, 150.37, 149.36, 148.20, 137.31, 128.65, 127.90, 127.36, 
125.52, 121.16, 113.83, 113.61, 110.07, 96.32, 92.66, 71.12, 56.52, 
56.25, 55.85; HRMS (m/z): [M+H]+ calcd. for C25H23O6, 419.14891; 
found, 419.14962. 
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 (E)-3-(3-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-4-
methoxyphenyl)-5,7-dimethoxy-4H-chromen-4-one (10) 
 
 
 
Pale White Solid (Yield 88%); mp: 92-93.3 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.28. 
 
1H NMR (400 MHz, CDCl3): δH 7.76 (s, 1H, H-2), 7.22 (d, J = 2.0 Hz, 
1H, H-2’), 7.02 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H, H-6’), 6.88 (d, J = 8.0 
Hz, 1H, H-5’), 6.43 (d, J = 2.0 Hz, 1H, H-6), 6.36 (d, J = 2.0 Hz, 1H, 
H-8), 5.55 (t, J = 6.0 Hz, 1H, CH), 5.09 (t, J = 6.0 Hz, 1H, CH), 4.62 
(d, J = 6.0 Hz, 2H, CH2), 3.94 (s, 3H, OCH3), 3.88 (s, 6H, OCH3), 
2.10-2.04 (m, 4H, CH2), 1.71 (s, 3H, CH3), 1.66 (s, 3H, CH3), 1.59 (s, 
3H, CH3); 13C NMR (100 MHz, CDCl3): δC 175.47, 163.96, 161.59, 
159.97, 150.27, 149.50, 148.04, 140.80, 131.78, 126.14, 124.79, 
124.09, 121.51, 119.78, 114.70, 111.24, 110.07, 96.28, 92.64, 66.08, 
56.50, 56.03, 55.84, 39.72, 26.44, 25.78, 17.79, 16.85; HRMS (m/z): 
[M + H]+ calcd. for C23H25O6, 465.22717; found, 465.22743.  
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 (E)-3-(4-((3,7-dimethylocta-2,6-dien-1-yl)oxy)-3-
methoxyphenyl)-5,7-dimethoxy-4H-chromen-4-one (11) 
 
 
 
Pale White Solid (Yield 89%); mp: 93.5-95.3 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.34. 
 
1H NMR (400 MHz, CDCl3): δH 7.79 (s, 1H, H-2), 7.23 (s, 1H, H-2’), 
6.95 (d, J = 8.0 Hz, 1H, H-6’), 6.88 (d, J = 8.0 Hz, 1H, H-5’), 6.43 (d, 
J = 2.0 Hz, 1H, H-6), 6.37 (d, J = 2.0 Hz, 1H, H-8), 5.52 (t, J = 6.0 
Hz, 1H, CH), 5.07 (t, J = 6.0 Hz, 1H, CH), 4.63 (d, J = 8.0 Hz, 2H, 
CH2), 3.93 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 
2.09 (d, J = 6.0 Hz, 2H, CH2), 2.06 (d, J = 5.6 Hz, 2H, CH2), 1.72 (s, 
3H, CH3), 1.67 (s, 3H, CH3), 1.59 (s, 3H, CH3); 13C NMR (100 MHz, 
CDCl3): δC 175.49, 163.97, 161.58, 159.96, 150.29, 149.11, 148.30, 
140.61, 131.82, 126.10, 124.95, 124.01, 121.12, 119.96, 113.19, 
112.92, 110.04, 96.28, 92.64, 66.00, 56.49, 56.11, 55.83, 39.66, 26.39, 
25.79, 17.80, 16.80; HRMS (m/z): [M+H]+ calcd. for C25H20F3O5, 
465.22717; found, 465.22715. 
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  79 
5,7-dimethoxy-3-(4-methoxy-3-((4-
(trifluoromethyl)benzyl)oxy)phenyl)-4H-chromen-4-one (12) 
 
 
 
Pale White Solid (Yield 92%); mp: 131-134 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.32. 
 
1H NMR (400 MHz, CDCl3): δH 7.73 (s, 1H, H-2), 7.63-7.57 (m, 4H, 
H-2”, H-3”, H-5” and H-6”), 7.29 (d, J = 1.6 Hz, 1H, H-2’), 7.05 (dd, 
J  = 8.0 Hz, J  =2 Hz, 1H, H-6’), 6.92 (d, J = 8.0 Hz,1H, H-5’), 6.43 
(d, J = 2.0 Hz, 1H, H-6), 6.37 (d, J = 1.6 Hz, 1H, H-8), 5.22 (s, 2H, 
CH2) 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.88 (s, 3H, OCH3); 13C 
NMR (100 MHz, CDCl3): δC 175.47, 164.06, 161.60, 159.99, 150.33, 
149.78, 147.58, 141.43, 127.58, 125.82, 125.59, 125.55, 124.98, 
122.31, 115.70, 111.75, 110.03, 96.36, 92.68, 70.42, 56.53, 56.15, 
55.86; HRMS (m/z): [M+H]+ calcd. for C26H22F3O6, 487.13630; 
found, 487.13656.  
 
  
  80 
5,7-dimethoxy-3-(3-methoxy-4-((4-
(trifluoromethyl)benzyl)oxy)phenyl)-4H-chromen-4-one (13) 
 
 
 
White Solid (Yield 94%); mp: 136.8-137.9 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.32. 
 
1H NMR (400 MHz, CDCl3): δH 8.02 (d, J = 8.0 Hz, 2H, H-5” and H-
3”), 7.71 (s, 1H, H-2), 7.52 (d, J = 8.0 Hz, 2H, H-2” and H-6”), 7.06 
(s, 1H, H-2’), 7.04 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H, H-6’), 6.92 (d, J = 
1.6 Hz, 1H, H-5’),  6.43 (d, J = 2.0 Hz, 1H, H-6), 6.37 (d, J = 1.6 Hz, 
1H, H-8), 5.22 (s, 2H, CH2), 3.93 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 
3.88 (s, 3H, OCH3); 13C NMR (100 MHz, CDCl3): δC 175.44, 167.07, 
164.02, 161.58, 159.97, 150.31, 149.76, 147.64, 142.59, 129.93, 
129.61, 127.14, 125.85, 124.93, 122.30, 115.66, 111.73, 110.02, 
96.33, 92.66, 70.61, 56.52, 56.16, 55.85, 52.20, 29.82; HRMS (m/z): 
[M+H]+ calcd. for C26H22F3O6, 487.13630; found, 487.13647. 
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5,7-dimethoxy-3-(3-((4-(trifluoromethyl)benzyl)oxy)phenyl)-4H-
chromen-4-one (14) 
 
 
 
White Solid (Yield 91%); mp: 136.5-137 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.31. 
 
1H NMR (400 MHz, CDCl3): δH 7.80 (s, 1H, H-2), 7.64 (d, J = 8.0 Hz, 
2H, H-5” and H-6”), 7.56 (d, J = 8.0 Hz, 2H, H-2” and H-3”), 7.33-
7.29 (m, 2H, H-2’ and H-5’), 7.09 (d, J = 8.0 Hz, 1H, H-6’), 6.96 (dd, 
J = 8.0 Hz, J = 2.4 Hz, 1H, H-4’), 6.45 (d, J = 2.4 Hz, 1H, H-6), 6.39 
(d, J = 2.4 Hz, 1H, H-8), 5.16 (s, 2H, CH2), 3.95 (s, 3H, OCH3), 3.98 
(s, 3H, OCH3); 13C NMR (100 MHz, CDCl3): δC 175.19, 164.13, 
161.65, 159.99, 158.35, 150.86, 141.32, 133.75, 130.29, 129.97, 
129.44, 127.52, 126.10, 125.63, 125.60, 122.01, 115.80, 114.98, 
110.08, 96.43, 92.72, 69.27, 56.52, 55.88; HRMS (m/z): [M+H]+ 
calcd. for C23H25O6, 457.12573; found, 457.12543. 
 
  
  83 
3-(3,4-bis(benzyloxy)phenyl)-5,7-dimethoxy-4H-chromen-4-one 
(15) 
 
 
 
Pale Yellow Solid (Yield 90%); mp: 144.7-146.1 °C; TLC (Petroleum 
Ether:EtOAc, 3:2 v/v): Rf = 0.34. 
 
1H NMR (400 MHz, CDCl3): δH 7.61 (s, 1H, H-2), 7.36 (t, J = 8.0 Hz, 
1H, H-2’), 7.16-7.28 (m, 10H, H-2”, H-2”’, H-3”, H-3”’, H-4”, H-4”’, 
H-5”, H-5”’, H-6” and H-6”’), 6.91 (dd, J = 8.0 Hz, J = 1.2 Hz, 1H, 
H-6'), 6.85 (d, J = 8.0 Hz, 1H, H-5’), 6.33 (d, J = 2.0 Hz, 1H, H-6), 
6.27 (d, J = 2.0 Hz, 1H, H-8), 5.09 (s, 2H, CH2), 5.08 (s, 2H, CH2), 
3.84 (s, 3H, OCH3), 3.78 (s, 3H, OCH3); 13C NMR (100 MHz, 
CDCl3): δC 175.41, 163.99, 161.58, 159.95, 150.37, 149.01, 148.79, 
137.46, 128.56, 128.52, 127.84, 127.82, 127.59, 127.39, 125.69, 
122.19, 116.50, 114.95, 110.03, 96.31, 92.65, 71.47, 71.41, 56.50, 
  84 
55.83; HRMS (m/z): [M+H]+ calcd. for C31H27O6, 495.18022; found, 
495.17997. 
  85 
4-((5-(5,7-dimethoxy-4-oxo-4H-chromen-3-yl)-2-
methoxyphenoxy)methyl)benzonitrile (16) 
 
 
 
Pale Yellow Solid, (Yield 93%); mp: 178.5-180.1 °C; TLC (Petroleum 
Ether/EtOAc, 3:7 v/v): Rf = 0.36. 
 
1H NMR (400 MHz, CDCl3): δH 7.73 (s, 1H, H-2), 7.65 (d, J = 8.0 Hz, 
2H, H-3”,H-5”), 7.56 (d, J = 8.0 Hz, 2H, H-2”,H-6”), 7.29 (s, 1H, H-
2’), 7.03 (d; J = 2.0 Hz, 1H, H-6’), 6.92 (d, J = 8.0 Hz, 1H, H-5’), 6.43 
(d, J = 2.0 Hz, 1H, H-6), 6.37 (d, J = 2.0 Hz, 1H, H-8), 5.21 (s, 2H, 
CH2), 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.88 (s, 3H, OCH3); 
13C NMR (100 MHz, CDCl3): δC 175.46, 164.06, 161.55, 159.96, 
150.34, 149.73, 147.30, 142.86, 132.45, 127.74, 124.97, 122.38, 
115.80, 111.71, 111.59, 109.96, 96.36, 92.67, 77.48, 77.16, 76.84, 
70.23, 56.53, 56.10, 55.87; HRMS (m/z): [M+H]+ calcd. for 
C26H22NO6, 444.14416; found, 444.14302. 
 
  
  86 
Methyl-4-((5-(5,7-dimethoxy-4-oxo-4H-chromen-3-yl)-2-
methoxyphenoxy)methyl)benzoate (17) 
 
 
 
Pale White Solid (Yield 91%); mp: 182.4-183.3 °C; TLC (Petroleum 
Ether/EtOAc, 2:3 v/v): Rf = 0.33. 
 
1H NMR (400 MHz, CDCl3): δH 8.03 (d, J = 8.0 Hz, 2H, H-3” and H-
5”), 7.71 (s, 1H, H-2), 7.53 (d, J = 8.0 Hz, 2H, H-2” and H-6”), 7.06 
(dd, J = 8.0 Hz, J = 2.0 Hz, 1H, H-6’), 6.92 (d, J = 8.0 Hz, 1H, H-5’), 
6.43 (d, J = 2.0 Hz, 1H, H-6), 6.37 (d, J = 2.0 Hz, 1H, H-8), 5.23 (s, 
2H, CH2), 3.94 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 3.88 (s, 3H, 
OCH3); 13C NMR (100 MHz, CDCl3): δC 175.44, 164.06, 161.61, 
159.99, 150.42, 149.39, 147.75, 141.43, 130.26, 127.36, 126.05, 
125.66, 125.62, 121.17, 113.91, 113.69, 110.02, 104.61, 96.36, 92.68, 
70.37, 56.53, 56.23, 55.86; HRMS (m/z): [M+H]+ calcd. for C27H25O8, 
477.15439; found, 477.15582. 
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  88 
4-((5-(5,7-dimethoxy-4-oxo-4H-chromen-3-yl)-2-
methoxyphenoxy)methyl)benzamide (18) 
 
 
 
Pale White Solid (Yield 93%); mp: 219-221 °C; TLC (CHCl3/CH3OH, 
97:3 v/v): Rf = 0.32. 
 
1H NMR (400 MHz, CDCl3): δH 8.32 (s, 1H, NH), 8.21 (s, 1H, H-2), 
7.99 (s, 1H, NH), 7.89 (d, J = 8.0 Hz, 2H, H-3” and H-5”), 7.53 (d, J 
= 8.0 Hz, 2H, H-2” and H-6”), 7.39 (s, 1H, H-2’), 7.09 (d, J = 8.0 Hz, 
1H, H-6’), 7.02 (d, J = 8.0 Hz, 1H, H-5’), 6.67 (brd, 1H, H-6), 6.52 
(brd, 1H, H-8), 5.15 (s, 2H, CH2), 3.88 (s, 3H, OCH3), 3.83 (s, 3H, 
OCH3), 3.80 (s, 3H, OCH3); 13C NMR (100 MHz, (CD3)2SO): δC 
196.49, 173.67, 167.66, 163.64, 160.83, 159.18, 151.25, 148.95, 
147.12, 140.41, 133.75, 127.62, 127.34, 124.65, 124.54, 122.00, 
114.83, 111.79, 108.93, 96.22, 92.96, 79.20, 69.62, 56.13, 55.99, 
55.67; HRMS (m/z): [M+H]+ calcd. for C25H20F3O5, 457.12573; 
found, 457.12543. 
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  90 
5,7-dimethoxy-3-(4-methoxy-3-((4-nitrobenzyl)oxy)phenyl)-4H-
chromen-4-one (19) 
 
 
 
Pale White Solid (Yeld 95%); mp: 170.5-171.5 °C; TLC (Petroleum 
Ether/EtOAc, 2:3 v/v): Rf = 0.29. 
 
1H NMR (400 MHz, CDCl3): δH 8.22 (d, J = 8.0 Hz, 2H, H-3” and H-
5”), 7.74 (s, 1H, H-2), 7.64 (d, J = 8.0 Hz, 2H, H-2” and H-6”), 7.32 
(s, 1H, H-2’), 7.04 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H, H-6’), 6.93 (d, J = 
8.0 Hz, 1H, H-5’), 6.44 (d, J = 2.0 Hz, 1H, H-6), 6.37 (d, J = 2.0 Hz, 
1H, H-8), 5.27 (s, 2H, CH2), 3.95 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 
3.89 (s, 3H, OCH3); 13C NMR (100 MHz, CDCl3): δC 175.48, 164.10, 
161.57, 159.99, 150.37, 149.78, 147.61, 147.27, 144.92, 127.79, 
125.68, 125.02, 123.88, 122.48, 115.93, 111.77, 109.97, 96.38, 92.69, 
70.05, 56.53, 56.13, 55.88; HRMS (m/z): [M+H]+ calcd. for 
C25H22NO8, 464.13399; found, 464.13435.  
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B1.1 Marine alkaloids 
 
B1.1.1 Alkaloids Isolated from Marine Sponges of the 
Genus Haposclerida 
 
Sponges (Phylum Porifera) are usually described as the most 
primitive of all the multicellular organisms found in all the oceans of 
the world, at depths ranging from the shoreline to the deep abyssal 
plane. Sponges are typically betonic animals and, with the exception 
of about 150 species of freshwater, almost exclusively marine1-4. 
 
 
Figure 24 Papua New Guinea and Xestospongia Ingens sponge. 
About a third of all marine products and more than half of all 
alkaloids, have been isolated from sponges (Phylum Porifera). A 
group of these alkaloids contains compounds, that although 
structurally different, are characterized by the presence of a 3-
alkylpiperidine motif in their structure. 
The alkyl component of this common structural motif is often a 
linear, saturated or unsaturated chain, which ranges from eight to 
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sixteen carbon atoms. The heterocyclic component can instead be 
found in different oxidation states, pyridine, tetrahydropyridine or 
piperidine. About one third of the known members of this group, 
which are either simple monomers or oligomers or high molecular 
weight polymers, contain pyridine. The remaining two-thirds, which 
have more complex cyclic structures and appear to be biogenetically 
derived from macrocyclic dimers, instead present piperidine and 
tetrahydropyridine heterocycles (figure 25). 
The assumption of a common biogenetic origin is based on more 
evidence: perhaps the most important of these is the little diffusion in 
nature of a 3-alkylpiperidinic nucleus, so its presence in a group of 
metabolites isolated from members of a particular phylum represents 
a significant indication of the biogenetic correlation. Instead, the 
observation that the sponges, whose metabolites have the 3-
alkylpiperidinic nucleus, all belong to the order Haplosclerida, 
provides a taxonomic support about the common biogenetic origin. 
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Figure 25 Alkaloids from the marine sponges of the order Haplosclerida. 
 
B1.2 Structures of the Madangamines Alkaloids 
 
Madangamines are a small group of pentacyclic alkaloids isolated 
from marine sponges of the genus Haposclerida.  
Structurally are characterized by a perhydro-6,4-
(iminomethano)isoquinoline core (ABC)6, 7, 8 and by two linear carbon 
chains connecting N-7 to C-9 (D ring) and N-1 to C-3 (E ring). The 
western ring (D) differs in each madangamine in: 
 Dimension (13- to 15-membered ring); 
  106 
 Degree of unsaturations (one and three double bonds all in cis 
conformation); 
The same eastern ring (E) is shared among madangamines A-E 
(two unsaturations for 11-membered ring), meanwhile the 
madangamine F presents 4 unsaturations for 13-membered chain, and 
an hydroxyl group in C-4 position of the C ring (figure 26). 
The diazatricyclic core of these alkaloids shows a diamond-
lattice structure, in which A, B and C rings possess a chair 
conformation. In particular, one of these rings displays a flattened 
chair conformation, due to the sp2 hybridization of the C-3. 
Madangamines A-E exhibit four stereocentres, C-2, C-5, the 
quaternary C-9, and C-12, and a conformationally locked N-72, 3, 11 
(figure 25). The inability of that nitrogen to face the phenomenon of 
pyramidal inversion makes the lone pair locked within the core of the 
tricyclic system, and inaccessible to both protonation and formation of 
H-bond. As a consequence, the basicity of the N-7 decreases, as the 
polarity of the whole system. 
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Figure 26 Structures of madangamines. 
 
B1.3 Biological Activity 
 
As cited before, madangamines showed significant in vitro 
cytotoxic activity5 (figure26). In particular, madangamine A is 
endowed by in vitro cytotoxic activity against murine leukemia P388 
(ED50 0.93 g/mL) and human lung A549 (ED50 14 g/mL), brain 
U373 (ED50 5.1 g/mL), and breast MCF-7 (ED50 5.7 g/mL) cancer 
cell lines5. Madangamine F shows weak cytotoxicity against human 
CNS SF-295 (ED50 19.8 g/mL), human breast MDA-MB-435 (ED50 
16.2 g/mL), colon HCT-8 (ED50 > 25 g/mL) and leukemia HL-60 
(ED50 16.7 g/mL) cancer cell lines5. All tests were performed on 
MTT cell proliferation assay. Synthetic madangamine D also displays 
in vitro cytotoxicity against human colon HT29 (GI50 4.4 g/mL) and 
pancreas PSN1 (GI50 7.4 g/mL) cancer cell lines, but it is inactive 
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against lung NSCLC A549 and breast MDA-MB-231 cancer cell lines 
at the highest assayed concentration (10 g/mL). No bioactivity data 
have been reported for natural madangamines B-E5. 
 
 
Figure 27 Biological activities of madangamines. 
The continuous evaluation of the antitumor potential of new 
cytotoxic natural products is essential to overcome problems 
connected to the drug resistance. Natural madangamines A and F, and 
synthetic madangamine D showed promising EC50 values against 
several cancer cell lines. At the outset of this PhD thesis no further 
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biological data were available. At the same time, not even synthetic 
madangamine B was obtained and neither tested. The goal of Amat’s 
group was to totally synthesize (+)-madangamine B (figure 28), also 
in order to investigate how this complex macrocycle should affect 
cancer growth.  
 
Figure 28 Madangamine B.  
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Here, in this complex project, we describe the preparation of the 
ABC diazatricyclic core, in the synthesis of the fragments C-13/C-20 
(fundamental for E ring construction) and C-21/C-32 (necessary for D 
ring) and of the 8-oxomorphane, used as model to study the closure of 
E ring. 
 
B2.1 Synthetic Strategy 
 
The strategy to be followed for the synthesis of madangamine B 
was analogous to the one previously developed by Prof. Mercedes 
Amat and co-workers for the preparation of madangamine D11; this 
strategy entails the initial construction of the ABC diazatricyclic core, 
shared by madangamines A to E, and subsequent annulation of the 
macrocyclic D and E rings. 
 
The stereoselective construction of the fully functionalized 
diazatricyclic core in enantiopure form was carried out starting from 
lactam derivative 27a, the enantiomeric scaffold achieved through 
strereoselective cyclocondensation between (R)-phenylglycinol, a 
chiral inductor, and the oxoester 4-formyl-6-heptanoate (A route, 
scheme 2). 
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Scheme 2 Synthesis of the starting enantiomeric scaffold. 
 
A stereoselective conjugate addition on the corresponding 
unsaturated derivative, in which the double bond is activate by a 
carbonyl alkoxy group, leads to the introduction of an allyl substituent 
at C-12, leading to a cis-diallyl-substituted lactam (C-12, C-5). A 
RCM of the diallylic derivative was performed for the closure of the 
carbocyclic C ring, common in all madangamines. The generation of 
the quaternary stereocenter at the C-9 position, by alkylation of the 
enolate, takes advantage of the acidity of the hydrogen next to the 
carbonyl of the ester and of the amide-lactam. The shape of the cis-
octahydroisoquinoline allowed the selective approach of the 
alkylating reagent from the less hindered zone. In this way the 
introduction of the carbon chain with the opportune functionalization 
at the terminal position for the construction of the D ring was allowed. 
The subsequent removal of the phenylethanol moiety of the chiral 
inductor and the closure of the piperidine A ring by an intramolecular 
aminohydroxylation represented the final strategic steps necessary to 
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complete the synthesis of the diazatricyclic core of madangamines10 
(B route, scheme 3). 
 
 
Scheme 3 Construction of the diazatricyclilc core. 
 
For the closure of the macrocyclic D ring, not treated herein, the 
synthetic strategies depend on the synthesis of a 12-membered chain 
containing three unsaturations; meanwhile, for the closure of the 
unsaturated macrocycle E the introduction in C-3 position of an 8-
membered chain, containing two unsaturation in Z configuration, and 
a following macrolactamization will be necessary11. The first step 
involves a Wittig type olefination in which carbon-carbon double 
bond with the Z-configuration has to be stereoselectively generated (C 
route, scheme 4). 
 
  117 
 
Scheme 4 Synthetic strategy in madangamines construction. 
 
B2.2 Synthesis of the Diazatricyclic Core 
 
In this chapter it is described in details the synthetic steps adopted 
for the construction of the diazatryciclic core, starting from the lactam 
27a featuring the piperidine ring B and the C-5 stereocenter of these 
natural compounds. 
The general tranformations to obtain the desired ABC core is 
described in scheme 5. 
 
 
Scheme 5 Desired structure of the ABC core. 
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The first step of the synthesis is oriented to the building of the 
quinoline, presenting an hydroxymethyl group at the chiral C-9 
position, and a functionalized chain useful for the D ring closure in 
further steps. 
 
The key steps in the synthesis of cis-octahydroisoquinoline (37) 
are (scheme 6): 
1. Stereoselective conjugate addition (on C-12 position) of the 
allyl group to the unsaturated lactam derived from 27a; 
2. Olefin metathesis for closure of the ring C; 
3. Stereoselective alkylation in C-9; 
4. Removal of the phenylethanolic portion of the chiral inducer; 
5. Reduction of the carbonyl group of ester in C-9. 
 
 
Scheme 6 Key steps in synthesis of 37. 
In the cis-octahydroisoquinoline intermediate, the key 
stereocenters C-5, C-9 and C-12 were already present and, 
specifically, two of these were generated by stereoselective 
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conjugated addition (C-12) and alkylation of the enolate (C-9). 
Starting from compound 37, the key step to the final assembly of the 
diazatriciclic nucleus is the closure of the piperidine ring A. This was 
obtained by conversion of the hydroxymethyl group, bound to C-9, 
into an ethylamine group, followed by a reaction of amino-
hydroxylation of the carbon-carbon double bond present on the C ring 
of the cis-octahydroisoquinoline system10. 
 
B2.2.1 Synthesis of Enantiopure Lactam 27a 
 
Even if the synthesis of the lactam 27a is the same used for the 
preparation of madangamine D, the synthetic procedure is discussed 
in details.  
The first goal to reach in the synthesis was represented by the 
construction of the chiral “building block” 27a, starting from the 
commercially available (R)-(-)-2-phenylglycinol and a racemic -
oxoester, through a process that involves the dynamic kinetic 
resolution (scheme 7). 
Firstly the racemic intermediate 4-formyl-6-heptanoate 26 was 
obtained in 64% yield after treatment between metacrylate10 and 
enamine 1, obtained in turn from condensation of piperidine with 4-
pentenal.  
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Scheme 7 Synthesis of the 26 racemate. 
 
The cyclocondensation between 26 and the chiral inductor was 
carried out at 0 °C in presence of Na2SO4; the system was heated at 80 
°C under vacuum (10-15 mmHg), and, in the end, were afforded the 
stereoselective lactames 27a (kinetic product, 71% yield) and 27b 
(10% yield), respectively (scheme 8). 
 
 
Scheme 8 B ring assembly. 
 
The high stereoselectivity accomplished in the reaction can be 
exploited considering that the cyclocondensation proceeded through a 
Dynamic Kinetic Resolution (DKR) of the racemic substrate12-16. As 
shown in scheme 9, the mixture of the four oxazolidine 
diastereoisomers (a, b, c, d) generated from the reaction between 26 
and (R)-phenylglycinol, is in equilibrium with the corresponding 
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imines/enamines (A-B-A’). The lactonization step occurred via a 
transition state in which the allylic substituent of the six-membered 
chair-like is equatorial (oxazolidines c and d). The isomer 27a as 
major product denoted that the lactamization process occurred more 
quickly for the diastereoisomer c, in which the nucleophilic attack of 
the nitrogen on the carboxyl group took place on the less hindrance 
face, that one in anti than to the phenolic substituent (scheme 9). 
This stereoselective process is an optimal route in order to 
assembly both the piperidinic ring B and to generate the first 
stereocenter C-5 of the alkaloid’s scaffold. 
 
Scheme 9 Dynamic Kinetic Resolution process. 
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B2.2.2 Synthesis of Azabicyclic BC System 
 
The azabicyclic BC system construction can be achieved 
following these main stages (scheme 10): 
1. Stereoselective conjugate addition; 
2. Ring Closing Metathesis (RCM) reaction; 
3. Stereoselective alkylation at C-9. 
 
 
Scheme 10 Synthesis of functionalized azabicyclic system. 
 
B2.2.3 Stereoselective Conjugate Addition 
 
The key reaction in the synthesis of azabicyclic core was the 
stereoselective conjugate addition on the lactam 29. 
Since the α,β-unsaturated lactams are poor Michael acceptors, the 
addition of a withdrawing group at C-9 was necessary to improve the 
reactivity of the intermediate 2917, 18.The withdrawing group selected 
was the methoxycarbonyl. 
Lactam 27a was treated sequentially with lithium 
bis(trismethylsilyl)amide, methyl chloroformate and phenylselenyl 
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chloride; the resulting mixture of epimers 28a/b was oxidized in 
presence of pyridine and H2O2 to afford compound 29. The 
intermediate 29 was employed in the next reaction without further 
purification. Conjugate addition of the allyl group to the α,β-
unsaturated lactam 29 was realized using allyl-magnesium bromide in 
presence of CuI, LiCl and TMSCl, yielding a mixture of epimers 
30a/b at C-919 (scheme 12). 
 
 
Scheme 11 Preparation of unsaturated lactam 29. 
 
 
Scheme 12 Stereoselective conjugated addition. 
The origin of this high stereoselectivity can be explain 
considering the rigid structure assumed by these compounds, due to 
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the presence of the amide bond, and to the conformation of the six 
membered ring, defined by the N-1 configuration. As a consequence, 
they adopt a pseudo-chair conformation (scheme 13) in which the allyl 
group is placed in pseudo equatorial position. The nucleophilic attack 
occurs under stereoelectonic control, leading to the formation of the 
kinetically favourite cis isomer. 
 
Scheme 13 Stereoelectronic control during the conjugate addition. 
The intermediate obtained was really important, since it 
constitued the precursor of the azabicyclic system and brings to the 
introduction of the C-12 stereocenter. 
 
B2.2.4 Olefin Metathesis 
 
The synthesis of the azabicyclic intermediate 32 occurred via 
olefin RCM reaction on the diallyl compound 30, which was 
converted in the tricyclic lactam 31 after treatment with second 
generation Grubbs catalyst in dichloromethane (DCM). The 
substituent present at the C-9 of the system activates the hydrogen in 
α-position of the carbonyl group, making it more acidic, and 
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represents the suitable precursor of the methyl-amino chain, necessary 
for the closure of the A ring of madangamines. 
The alkylation of the mixture of C-9 epimers of compound 31 is 
totally stereoselective; in fact the product 32 is obtained as only isomer 
in high yield (scheme 14). 
 
 
Scheme 14 Synthesis of compound 32. 
Olefin metathesis reactions have influenced the organic 
chemistry synthesis in the last 15 years20-24.  
Numerous synthetic transformations displayed by this reaction, 
when applied on suitable substrates, is until now still intriguing, since 
the same catalytic systems (initiators) can promote several reactions 
accordingly to the substrates and to the conditions’ reaction used 
(scheme 15). 
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Scheme 15 Olefin metathesis reaction largely employed in organic chemistry. 
 
B2.2.4.1 Catalysts 
 
Nowadays, the ability to display success in a such surprising 
variety of reactions is due, partly, to the large amount of catalysts 
commercially available, all endowed by strong activity and tolerance 
towards different functional groups.  
 
Figure 29 Olefin Metathesis catalysts. 
The first catalysts employed in olefin metathesis, described by 
Katz et al., were represented by tungsten-carbene units25-29, until the 
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molybdenum based catalyst I come in vogue in 1990s by Schrock and 
co-workers, representing the first real innovation in field of catalysts30. 
Compound I, if on the one hand can be exerted in a wide range of 
reactions31-34, on the other hand has drawbacks due to their sensitivity 
after exposure to oxygen, humidity and several polar functional 
groups35. Further, Grubbs and co-workers introduced the ruthenium-
based catalyst II36-39. The first generation Grubbs catalyst (II) even if 
gifted of weaker activity than to the Schrock catalyst I, exhibited better 
tolerance towards different functional groups and high stability, once 
exposed to atmosphere conditions. With the aim to improve the 
catalytic activity of the catalysts, the ligands of ruthenium atom were 
modified; the substitution of a phosphine group with a N-heterocycle 
led to the second generation Grubbs catalyst III40-43, which showed 
higher catalytic activity, higher thermic stability and more tolerance 
towards functional groups (figure 29). Despite these advances, the 
research for increasingly effective and selective catalysts continues44-
49.  
 
B2.2.4.2 Mechanism 
 
The explanation of the metathesis reaction mechanism was the 
culmination of nearly two decades of extensive research, and the 
subject of a lively debate among numerous research groups of that 
period. The mechanism originally proposed was the one by Hérisson 
and Chauvin in 197150, and the experimental proofs for its validity 
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were subsequently provided by Casey51, Katz52-54, and involving metal 
carbenes as propagators in the catalytic cycle. As shown in the scheme 
16, in the initial phase (a) of the reaction the catalysts binds the olefinic 
substrate through a process [2+2] leading to a metal cyclobutene 
intermediate. A retro cycloaddition [2+2] to opposite direction defined 
the depletion of an olefin moiety (ethylene in that case) to form a new 
metal carbene specie (b), a suitable intermediate able to generate a new 
metallic cycle, after addition of an olefinic molecule. This cycle faced 
subsequently a disruption accomplished by the generation of a new 
olefinic product (d) and by the release of the initial catalyst, again 
available for further conversions (scheme 16). 
 
 
Scheme 16 General aspects of olefin metathesis. 
 
B2.2.5 Formation of the Endocyclic Double Bond 
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The formation of the C ring of madangamines’system was 
accomplished by a ring closing metathesis reaction of the diallylic 
moieties using the second generation Grubbs catalyst III. Compound 
31, thus obtained, showed the azabicyclic system and an endocyclic 
double-bond, a fundamental requisite for the building of ABC nucleus 
of madangamines (scheme 17). 
 
 
Scheme 17 C ring closure. 
 
B2.2.6 Stereoselective Alkylation 
 
With the availability of compound 31, the generation of C-9 
quaternary centre was performed by taking advantage of either the 
remaining methine proton and the convex conformation of the cis-
hydroisoquinolone framework. The methoxycarbonyl works as 
precursor of the methylamino chain, fundamental for the A ring 
closure, improving the acidity of the H in α-position of carbonyl group 
(scheme 18). 
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Scheme 18 Stereoselective alkylation: C-9 generation. 
The alkylation was performed using the 2-(2-bromoethyl)-1,3-
dioxolane in presence of NaH as base, and TBAI (scheme 19); the 
latter was used to promote the interchange bromide/iodine during the 
reaction and improve the reactivity of the alkylating group. The 
dioxolane was chosen because in the last step of the synthesis the 
acetale should be hydrolyzed in aldehyde, leading to the building of D 
ring and, in the end, of the whole macrocycle. 
The reaction is highly stereoselective due to the geometry of the 
bicyclic system, which allowed an exo-alkylation. 
 
 
Scheme 19 Stereoselective alkylation. 
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B2.2.7 Removal of the Chiral Inductor 
 
At this point, the removal of the phenylethanol moiety from the 
chiral auxiliary was achieved by successive treatment of 32 with Na 
in liquid NH3 and LiAlH4, to give an N-unsubstituted piperidine-3-
methanol derivative, which was immediately protected as the N-Boc 
piperidine 37 (scheme 20). 
 
 
Scheme 20 C-N bond disruption. 
 
The reduction of organic molecules with a “solution of electrons” 
in ammonia is known as “dissolving metal reduction”. When alkali 
metals (lithium, sodium, potassium or calcium) are dissolved in liquid 
ammonia, the metal’s atoms lose their electrons which impair a typical 
blue coloration to the solution. Unfortunately, even if these reductions 
are really effective, displayed poor selectivity. 
As expected, this treatment led to the formation, at the same time, 
of the corresponding alkoxy- and hydroxylactam products and 
products deriving from reduction of the ester group. 
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Treatment of the mixture of products obtained after Na/NH3 
reduction with an excess of LiAlH4 (15 eq.) in anhydrous dioxane 
allowed the reduction of both carbinolamine portion and two carbonyl 
groups (scheme 21). In the end, the amino function was protected with 
Boc- before proceeding with the next steps of the reaction. 
 
 
Scheme 21 Chiral inductor elimination: reduction. 
 
This approach was really efficient for the synthesis of azabicyclic 
intermediate, providing the elimination of the chiral inductor. 
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B2.2.8 Synthesis of Tricycle ABC 
 
Azabicyclic compound 37 owned two fundamental properties 
largely exploited for the synthesis of ABC system: 
1. Primary alcohol in C-9, with a precise spacial 
arrangement, should be easly converted in amino function; 
2. Double bond in C ring, should allow the reaction of 
epoxydation/intramolecular ring opening to form the 
diazatricyclic core and the two stereocenters C-2 and C-3. 
The piperidine ring A was realized through an amino-
hydroxylation on the double bond in the ring C (scheme 22). 
 
 
Scheme 22 Diazatricyclic nucleus assembly. 
The synthetic strategy started with the transformation of the 
alcoholic moiety in 37 in an azide. The procedure envisaged first of 
all the transformation of the alcohol in a mesylate intermediate 38, 
yielding the desired product 39 without effort and under drastic 
conditions of reaction (scheme 23).  
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Scheme 23 Synthesis of compound 39. 
 
Treatment of azide intermediate 39 with m-chloroperbenzoic acid 
led to the non-isolable epoxide; further reaction proceeded with 
perfect selectivity affording only one isomer (scheme 24); this high 
selectivity should be explained considering that the reaction of 
epoxidation occurred on the less hindered face of the bicyclic system. 
 
 
Scheme 24 Stereoselective epoxidation. 
The resulting compound 40 was selectively reduced through the 
Staudinger reaction at the azide moiety. The amino epoxide derivative 
cycled spontaneously, leading to the diazatricyclic alcohol 41. The 
analysis of the product 41 showed that the amino chain drives the endo 
nucleophilic attack on the epoxidic ring (scheme 25). 
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Scheme 25 A ring closure. 
The free amino group was so protected with tosyl chloride, 
meanwhile the alcoholic residue in C-3 was oxidized in ketone 
through the use of Dess-Martin periodinane (scheme 26). 
 
 
Scheme 26 ABC diazatricyclic core formation.  
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B2.3 Synthesis of C-13/C-20 Fragment 
 
The synthesis of the fragment C-13/C-20 started with a Z-
selective Wittig reaction between the phosphonium salt 49 and the 
methyl-5-oxo-heptanoate 46. This fragment is really important for the 
construction of the E ring of madangamine B. It is an 8-membered 
chain presenting one Z unsaturation and a phosphonium salt moiety; 
that portion is fundamental to realize the anchorage by Wittig reaction 
between the diazatricycle core and this fragment. 
The aldehyde was synthesized starting from the commercially 
available -valerolacton through these subsequential steps (scheme 
27): 
1. Hydrolysis/esterification in presence of 
H2SO4/MeOH; 
2.  Oxidation in presence of pyridinium chloro chromate 
(PCC). 
 
 
Scheme 27 Synthesis of aldehyde 46. 
Phosphonium salt was synthesized starting from 3-bromo 
propan-1-ol, previously protected with tert-butyldimethylsylil 
chloride, and triphenylphosphine (scheme 28). 
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Scheme 28 Preparation of phosphonium salt 49. 
 
Reaction between the phosphonium salt 49 and the linear 
aldehyde 46, in presence of NaHMDS as base55, 56 afforded the 
compound 50 as unique Z isomer, with a 78% yield (scheme 29). 
 
 
Scheme 29 Wittig reaction to afford Z intermediate 50. 
The synthesis of the chain was accomplished via: 
1.  O-deprotection; 
2.  Formation of bromo derivate 52, occurred first of all 
through the formation of the mesylate intermediate, and 
secondly by bromination of the mentioned mesylate; 
3.  Final transformation in phosphonium salt 53 (scheme 
30). 
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Scheme 30 Synthesis of phosphonium salt 53. 
The synthetic route to perform the assembly of the E ring should 
involve (i) the direct installation of the eight-membered carbon chain 
53 at C-3 position and (ii) the subsequent annulation of the E ring 
through an intramolecular macrolactamization. So, the required Z,Z 
poliunsaturated system could be directly installed to the diazatricycle 
43 using a Z-selective Wittig reaction with the corresponding 
phosphonium salt. Even if I didn’t take part in that step of the 
synthesis, it is a key reaction in the total synthesis of madangamines, 
and I would like to evaluate the topic aspects of this reaction. 
 
B2.3.1 Wittig Reaction 
 
Fundamental to obtain good results in Wittig reaction is the 
presence of an anhydrous phosphonium salt. This effect was reached 
treating the phosphonium salt, strongly hygroscopic, with 
phosphorous pentoxide under vacuum for several days at 80 °C. 
 
B2.3.1.1 Phosphorous Ylides 
 
The Wittig reaction was realized between a phosphorous ylide 
and an aldehyde or a ketone (scheme 31). Since its discovery, this 
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reaction is nowaday still considered a really important reaction among 
the ones in organic chemistry, due to its simplicity and efficiency57-63. 
 
 
Scheme 31 Schematic Wittig reaction. 
Initially, not much attention was paid to the stereochemistry of 
the reaction, since the products obtained were isolated as mixtures of 
Z/E isomers. More recently, however, it has been observed that 
depending on the ylide, on the carbonyl compound and on the reaction 
conditions it was possible to control the stereoselectivity of the 
reaction, favoring the formation of an isomer with respect to the other. 
The phosphorus ylides were classified (Figure 30) on the basis of their 
reactivity in: 
i. "stabilized" ylides which have groups such as -
COOMe, -CN, or -SO2Ar on the carbon atom of the hylide 
and which give predominantly E-alkenes; 
ii. "semi-stabilized" ylides which have slightly 
conjugated groups such as -Ph or allyl and which generally 
give a mixture of E/Z alkenes in a 1: 1 ratio; 
iii. "non-stabilized" ylide which give mainly Z-alkenes64, 
65.  
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Figure 30 Different types of ylides. 
 
Despite the promising progresses obtained for “stabilized” and 
“semi-satbilized” phosphonium salts, in this thesis we will treat the 
studies concerning the “non stabilized” ylides, since they are the ones 
used in this synthesis.  
 
B2.3.1.2 About the Mechanism 
 
In the original Wittig proposal, the nucleophilic addition of the 
ylide to the carbonyl compound led to the formation of the betainic 
intermediate, which will close to form a four-term cycle66, 67 (1,2-
oxyphosphethane). 
Although the existence of betaine has not been fully verified, this 
hypothesis has gained wide acceptance. 
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Scheme 32 Initial mechanism to explain the Wittig reaction. 
However, in 1973 Vedejs revolutionized the reaction mechanism 
until that moment proposed. In fact, he observed, by means of 
spectroscopy 31P NMR, that the only intermediates were the 
oxaphosphetanes68, 69 (Scheme 32). Consequently, the E/Z ratio of the 
alkenes produced was established by the cis/trans ratio of the 
oxaphosphethanes, suggesting that the stereochemistry was controlled 
in the transition state of the reaction70. Taking into account these last 
results, the selectivity Z could be explained considering two distinct 
processes: 
i. The irreversible addition of the ylide to the carbonyl 
compound, which produced two intermediates, 
oxyphosphetane diasteroisomers; 
ii. The stereospecific decomposition of the 
oxaphosphetane in alkene (Scheme 33). 
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Scheme 33 Modification of the previous mechanism proposed. 
The motivation for the preferential formation of cis-
oxaphosphetane stimulated Vedejs and Marth to elaborate a theory. 
Without going into detail, it was sufficient to say that there was a good 
reason to believe that if the ylide and the carbonyl compound reacted 
together to give an oxaphosphetane compound, they will do it by 
approaching each other, keeping the large substituents as far away as 
possible from each other.  
Furthermore, by playing on steric interactions it was clear how 
the cis geometry of the theory, above-mentioned, was favoured with 
respect to the trans, because of the smaller interactions 1,2 and 1,3, 
respectively between the Y substituent of the ylide and the larger 
substituent R of the carbonyl and between the phenyl and the smallest 
substituent H (scheme 34). 
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Scheme 34 Geometrical interactions. 
 
The suggestions provided from these theoretical considerations 
helped us to understand the Z selective nature of the Wittig reaction, 
which conferred the desired product in the suitable stereochemical 
geometry. 
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B2.4 Synthesis of Fragment C-21/C-32 
 
The fragment C-21/C-32 represents the chain of the D ring. This 
is an 11-membered chain, featuting three unsaturations, two in Z 
configuration and one in E configuration. The Z unsaturations derived 
from the synthesis of the fragment treated in this chapter, meanwhile 
the E unsaturation is going to be generated from the alkyl moiety 
already present in C-9 of the diazatricyclic core. 
 
Figure 31 Madangamine B. 
 
The synthesis of the fragment C-21/C-32 started with the 
protection of the 4-butyn-1-ol by treatment of 54 with TIPSCl 
protecting group. The presence of TIPS prooved be really useful in the 
D ring closure. 
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Scheme 35 TIPS protection of 4-butyn-1-ol 54. 
Tips protection of primary alcohol is a procedure used since 
197471, 72 and was largely describe by Rucker73. The TIPS ether was 
easily obtained from but-3-yn-1-ol in DMF and DCM in the presence 
of imidazole. The reaction yielded product 55 in 89% (scheme 35). 
The following step was fundamental for the introduction of a new 
primary alcoholic function, since it represented the suitable substrate 
for the further synthesis of the total 11-membered chain. The reaction 
was realized in presence of the intermediate 55, n-BuLi and activated 
formaldehyde, and afforded after 5 hours the compound 56 in 87% 
yield (scheme 36). 
 
Scheme 36 Synthesis of 56 molecule. 
 
Chain conjugation occurred after the treatment of tosylate 
intermediate 57 with NaI, CuI as catalysts, K2CO3 as base, yielding 
product 58 (86% overall yield of  two steps, scheme 37). This 
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conjugated molecule was selectively reduced, affording the 
corresponding cis diene. 
 
 
Scheme 37 Synthesis of conjugate alkyne 58. 
 
B2.4.1 Stereoselective Reduction 
 
 
Scheme 38 Synthesis of conjugate cis-alkene 59. 
 
Conjugate alkyne was treated with Nickel acetate, in presence of 
solid NaBH4, ethylendiammine in MeOH and, obviously, H2 
atmosphere; cis alkene 59 was obtained in high yield, due to the 
“reducing” system formed in situ from the above-mentioned reagents 
(scheme 38). Nickel (II) acetate was in fact reduced by borohydride, 
in MeOH, affording the P-2 nickel, a colloidal non-magnetic black 
catalyst (the formation of the colloid was well appreciated by 
observing the change of colour: from sea green to black). The presence 
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of ethylendiamine was really important to favor the production of cis 
alkenes. The reduction was completed once the atmosphere was fixed 
with hydrogen. 
The precise methodology to follow was: 
i. Addition of Ni(OAc)2 ∙ 4 H2O in anhydrous methanol; 
ii. Addition of NaBH4 portion wise (coloration of the 
solution from sea green to black); 
iii. Addition of EDA and stirring for 20 minutes under 
Argon atmosphere; 
iv. Addition of alkyne and replacement of the Ar 
atmosphere with the H2 atmosphere. 
 
B2.4.2 Iodination 
 
Once the alcohol 59 was purified, the alcoholic residue was 
functionalized with mesyl chloride, in order to afford the iodine 
derivative, necessary for the D ring closure in madangamine system 
(Scheme 39). Different syntheses were elaborated, involving 
principally Br-, Cl- and I- as halogens; iodine derivate afforded the 
best results in term of yield. 
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Scheme 39 Iodination of bis-alkene 59. 
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B2.5 Closure of D Ring and E Ring of Madangamines: 
Synthesis of a Model 
 
The synthesis of the 8-oxomorphan, a model largely used to study 
how to assemble the (Z, Z)-unsaturated 11-membered eastern E ring 
of madangamines, has been described below. The studies on that 
model were and are crucial, since the overall yield of the synthesis of 
the diazatricyclic core afforded really few amount of product. It is not 
rational use the ABC core for the different reactions employed to reach 
the total synthesis of madangamine B. In this context, a short and 
useful synthetic sequence was chosen to assembly the suitable 
functionalized morphan derivative 69, which mimics rings A and C of 
the alkaloids from commercially available 4-vinylcyclohexene75. 
Synthetically speaking, the exocyclic double bond of the starting 
compound was selectively hydroborated by sequential treatment with 
disiamylborane. The following oxidative work-up yielded. the alcohol 
64, which was conveniently converted into the corresponding azide 
66. Further, epoxidation of the double bond, by treatment with m-
chloroperbenzoic acid, and a Staudinger reduction of the azide 
functionality occurred (scheme 40). Notably, the synthesis of the azide 
required less drastic conditions than the ones employed towards the 
synthesis of ABC core. The amino epoxide intermediate underwent a 
smooth in situ cyclization, directly leading to an intermediate amino 
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alcohol, which was then N-protected with a tosyl chloride group and 
oxidized in presence of Dess-Martin periodinane (scheme 41).  
 
Scheme 40 Synthetic strategy for the building of 8-bicyclic system 67. 
According to the literature75, even if the tosyl protecting group 
afforded the product endowed of less yield, it was considered the best 
intermediate for the further study of E ring closure.  
 
Scheme 41 Synthesis of 8-oxomorphan 69. 
 
Nowadays, the total synthesis of madangamine B is momentarily 
shelved to favor the pentacycle madangamine A. This change on focus 
is due to the fact that, even if the above-mentioned D chain 
accomplishes positive results on the synthesized model, it seems not 
working on the ABC tricycle core of madangamines, leading to 
negative results.  
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B2.6 Experiment  al Section 
 
B2.6.1 General Methods for UB project 
 
All non-aqueous reactions were performed under an argon atmosphere 
using flame-dried and standard syringe/septa techniques. 
All the reagents were purchased from Sigma-Aldrich or Alpha Aesar 
and used without further purification. 
Reactions were magnetically stirred and monitored by TLC performed 
on Merck TLC alluminium sheets (silica gel 60 F245). Spots were 
visualized with UV light (= 254 nm) or through staining with KMnO4 
1% aqueous solution. 
Chromatographic purification of products (Flash Chromatography) 
was performed using SDS silica gel 60 ACC, 35-75 mm, 230-240 
mesh ASTM.  
Instrument FT-IR: Nicolet Avantar 320 FT-IR.  
Optical rotations α: were measured on a Perkin-Elmer 241 and values 
are reported as follows [α]D22=10-1 deg cm2 g-1.  
High Resolution Mass-Spectra (HMRS)were measured on a LC/MSD 
TOF Agilent Technologies, made at Centres Cientìfics i Tecnologics 
of Barcelona University.  
NMR 1H and 13C spectra were recorder in CDCl3 at 300 or 400 MHz 
(1H ) and at 75.4 o 100.6 MHz (13C). Chemical shifts () are reported 
in ppm and are referenced to CDCl3 (=7.26 ppm for 1H , =77.16 ppm 
for 13C). All 13C spectra were measured with complete proton 
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decoupling. TMS is used as internal standard. Data for NMR spectra 
are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, br = broad signal, J = coupling constant in Hz. 
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B2.7 Synthesis of Tricycle ABC 
 
Methyl-4-formyl-6-heptanoate (26) 
 
 
 
In a two-necked round-bottom flask, 4-pentanal (4.7 ml, 0.047 mol) 
was added dropwise to a dry solution of K2CO3 (2.0 g, 0.014 mol) in 
piperidine (12 mL, 0.1 mol) during 30 minutes, at 0 °C. The reaction 
was stirred for two days at room temperature, and filtered on sintered 
glass filter. The residue, carefully washed with Et2O, contains the 
enamine. 
To a solution of methyl-acrylate (7.5 mL, 0.0833 mol) in dry 
acetonitrile (75 mL), a solution of the enamine in dry acetonitrile (19 
mL) was added at 5 °C. The reaction was stirred at room temperature 
overnight, and refluxed for 72 hours. After addition of glacial acetic 
acid (10.5 mL) in H2O (75 mL) the reaction was refluxed for 72 hours. 
Et2O was then added and the organic phase was washed with HCl 3N 
(100 mL), saturated solution of NaHCO3 (100 mL) and NaCl saturated 
solution (100 mL). The combined organic extracts were dried on 
MgSO4 and concentrated in vacuo. The residue methyl-4-formyl-6-
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heptanoate was used in the next reaction without further purification 
(brown oil, 5.12 g, 0.030 mol, 64% yield). 
 
1H NMR (300 MHz, CDCl3): H 9.63 (d, J = 2.1 Hz, 1H, CHO), 5.76 
(m, 1H, H- 6, m), 5.09 (m, 2H, H-7), 3.67 (s, 3H, CH3), 2.51-2.21 (m, 
5H, 2H-2, H-4, 2H-5), 1.98 (m, 1H, H-3), 1.80 (m, 1H, H-3). 13C 
NMR (100.6 MHz, CDCl3): C 203.7, 173.4, 134.3, 117.6, 51.7, 50.3, 
32.9, 31.2, 23.2. 
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(3R, 8S, 8aR)-8-Allyl-5-oxo-3-phenyl-2,3,6,7,8,8a-hexahydro-5H-
oxazolo[3,2-a]pyridine (27a) 
 
 
In a two-necked round-bottom flask, a solution of racemic methyl-4-
formyl-6-heptanoate (4.6 g, 29 mmol), (R)-(-)-2-phenylglicynol (3.97 
g, 29 mmol) and dry Na2SO4 in Et2O (115 mL) was stirred overnight 
at 0 C. The resulting suspension was filtered on Celite. The organic 
mixture was concentrated in vacuo and the residue was heated at 80 
C for 18 h under vacuum (10.15 mmHg). The residual mixture of 
products was purified by FC (n-Hex/EtOAc 8:2  0:10) and afforded 
27a (5.3 g, 20.59 mmol, 71%) and (8S, 8aS)-diastereoisomer 27b (2.9 
g, 0.75 g, 10%). 
 
Major isomer 27a  
1H NMR (400 MHz, CDCl3, COSY, gHSQC): H 7.30-7.20 (m, 5H, 
C6H5), 5.86 (dddd, J = 16.5, 10.2, 7.8, 6.0 Hz, 1H, CH=), 5.12 (m, 2H, 
CH2=), 4.92 (d, J = 6.6 Hz ,1H, H-3), 4.53 (d, J = 8.7 Hz, 1H, H-8a), 
4.11 (dd, J = 9.0, 6.9 Hz 1H, H-2), 4.01 (dd, J = 9.0, 1.2 Hz, 1H, H-
2), 2.62 (m, 1H, CH2 allyl), 2.42 (ddd, J = 18.0, 7.2, 1.8 Hz, 1H, H-6), 
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2.30 (ddd, J = 18.0, 12.0, 6.6 Hz, 1H, H-6), 2.02 (m, 3H, H-7, H-8, 
CH2 allyl), 1.45 (dddd, J = 13.8, 13.8, 12.0, 7.2 Hz 1H, H-7). 13C NMR 
(100.6 MHz, CDCl3): C 167.1, 141.4, 134.6, 127.4, 128.4, 126.2, 
117.4, 91.9, 73.7, 58.9, 39.1, 35.4, 31.2, 23.6. [𝒂]𝑫
𝟐𝟐: -32.8 (c 1.0, 
EtOH). IR (film): 1655 (NCO) cm-1. 
 
Minor isomer 27b 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): H 7.34-7.25 (m, 5H, 
C6H5), 5.83 (dddd, J = 16.5, 10.2, 8.1, 6.0 Hz, 1H, CH=), 5.25 (t, 1H, 
J = 7.8 Hz H-3), 5.13 (m, 2H, CH2=), 4.69 (d, J = 8.4 Hz, 1H, H-8a), 
4.47 (dd, J = 9.0, 8.1 Hz 1H, H-2), 3.75 (dd, J = 9.0, 7.8 Hz, 1H, H-
2), 2.56 (m, 1H, H-6, CH2 allyl), 2.35 (ddd, J = 18.6, 12.0, 6.6 Hz, 1H, 
H-6), 2.07 (dt, J = 16.5, 8.4, 8.4 Hz, 1H, CH2 allyl), 1.66 (m, 1H, H-
8), 1.53 (m, 1H, H-7). 13C NMR (100.6 MHz, CDCl3): C 168., 139.4, 
134.6, 127.4, 128.7, 126.0, 117.4, 92.0, 72.3, 58.3, 39.5, 35.8, 31.3, 
22.7. [𝒂]𝑫
𝟐𝟐: -59.9 (c 1.0, EtOH). IR (film): 1658 (NCO) cm-1. 
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(3R,8S,8aR)-methyl 8-allyl-5-oxo-3-phenyl-6-
(phenylselanyl)hexahydro-2H-oxazolo[3,2-a]pyridine-6-
carboxylate (28) 
 
In two-neck round-bottom flask LiHMDS (1M in THF 10 mL) was 
slowly added at -78 ºC to a solution of lactam 27a (2 g, 7.77 mmol) in 
dry THF (120 mL), and the resulting mixture was stirred for 90 
minutes. Then, methyl chloroformate (0.6 mL, 7.78 mmol) is added at 
-78 ºC and was stirred for 90 minutes. In the end, phenyl selenium 
chloride (2.08 g, 10.8 mmol) was added dropwise and stirred for 1 h. 
Reaction was quenched by adding NH4Cl saturated solution. The 
aqueous phase was extracted with EtOAc, and combined organic 
phases were dried over MgSO4. The organic layers were concentrated 
in vacuo and the residue was purified by FC (n-Hex-EtOAc 9:1  1:1) 
affording product 28 (3.14 g, 6.68 mmol, 86%), as a mixture of 
epimers at C-6. 
 
Epimer 28a 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): H 7.66-7.26 (m, 10H, 
ArH), 5.17 (dddd, J= 16.8, 10.4, 7.6, 6.4 Hz 1H, CH=), 5.03 (m, 2H, 
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CH2=), 4.87 (dd, J= 6.8, 2.0 Hz 1H, H-3,), 4.15 (d, J= 8.8 Hz, 1H, H-
8a,), 4.05 (dd, J= 9.2, 6.8 Hz, 1H, H-2), 4.00 (dd, J= 9.2, 2.0 Hz, 1H, 
H-2), 3.58 (s, 3H, CH3), 2.41 (m, 1H, H-7), 2.33 (dd, J = 14.0, 2.8 Hz, 
1H, CH2 allyl), 1.98 (m, 2H, H-7, H-8), 1.82 (dd, J=14.0, 12.4 Hz, 1H, 
CH2 allyl). 13C NMR (100.6 MHz, CDCl3): C 170.8, 163.3, 140.5, 
133.7, 138.2-126.4, 117.7, 91.8, 74.0, 59.4, 54.0, 53.0, 37.7, 36.6, 
34.8. [𝒂]𝑫
𝟐𝟐:-99.3 (c 0.7, CHCl3). IR (NaCl): 1667, 1725 cm-1. HRMS 
(m/z): [M+H]+ calcd for C24H25NO4Se, 71.0948; found 471.0955. 
 
Epimer 28b  
1H NMR (400 MHz, CDCl3, COSY, gHSQC): H 7.47- 7.23 (m, 10H, 
ArH), 5.59 (dddd, J = 16.0, 10.0, 8.0, 6.0 Hz, 1H, CH=), 4.97 (m, 3H, 
H-3, CH2=), 4.63 (d, J = 9.2 Hz, 1H, H-8a,), 4.17 (dd, J = 9.2, 6.8 Hz 
1H, H-2,), 4.10 (dd, J = 9.2, 1.2 Hz, 1H, H-2), 3.73 (s, 3H, CH3), 2.52 
(m, 1H, CH2 allyl), 2.32 (m, 1H, H-8), 2.08 (dd, J= 15.2, 4.0 Hz, 1H, 
H-7), 2.00 (dd, J = 15.2, 11.6 Hz, 1H, H-7), 1.98 (m, 1H, CH2 allyl). 
13C NMR (100.6 MHz, CDCl3): C 171.0, 162.8, 140.5, 134.0, 138.3- 
126.8, 117.8, 91.6, 73.8, 59.6, 55.6, 53.3, 36.5, 35.0, 33.6. [𝒂]𝑫
𝟐𝟐: + 
18.46 (c 0.5, CHCl3). HRMS (m/z): [M+H]+  calcd for C24H25NO4Se, 
471.0948; found  471.0946.  
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(3R,8S,8aR)-methyl-8-allyl-5-oxo-3-phenyl-3,5,8,8a-tetrahydro-
2H-oxazolo[3,2-a]pyridine-6-carboxylate (29) 
 
 
To a solution of a mixture of compounds 28a and 28b (1.6 g, 3.4 
mmol), H2O2 30% (0.73 mL, 23.8 mmol) and pyridine (0.36 mL, 4.4 
mmol) were added in DCM (231 mL); the resulting mixture was 
stirred for 2 h at room temperature. The two phases were separated 
and the organic layer was washed with water, dried over MgSO4, and 
concentrated in vacuum to give the crude as oil, which was stored at -
30 ºC and used in the next reaction without further purification.  
 
1H NMR (300 MHz, CDCl3): H 7.36-7.20 (m, 5H, ArH), 5.86 (dddd, 
J = 15.3, 10.8, 8.7, 5.7 Hz, 1H, CH=), 5.27 (m, 2H, CH2=), 5.03 (dd, 
J = 6.0, 2.4 Hz, 1H, H-3), 4.87 (d, J = 10.5 Hz, 1H, H-8a), 4.24 (dd, J 
= 9.0, 6.0 Hz, 1H, H-2), 4.20 (dd, J = 9.0, 2.4 Hz, 1H, H-2), 3.78 (s, 
3H, CH3), 2.91 (m, 1H, H-8), 2.7 (d, J = 14.4 Hz, 1H, CH2 allyl), 2.31 
(dt, J = 14.4, 8.7 Hz, 1H, CH2 allyl). 13C NMR (75.4 MHz, CDCl3): 
C 164.3, 157.3, 147.6, 140.2, 133.3, 129.7, 127.7, 128.5-126.8, 119.0, 
89.8, 74.4, 58.3, 52.3, 41.2, 33.5. IR (NaCl): 1673, 1741 cm-1. 
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(3R,7R,8S,8aR)-Methyl-7,8-diallyl-5-oxo-3-phenylhexahydro-2H-
oxazolo[3,2-a]pyridine-6-carboxylate (30) 
 
 
In a three-neck round-bottom flask of 250 mL LiCl (1.2 g, 28.4 mmol) 
was dried at 80 ºC for 1 h under vacuum (10-15 mmHg); in that flask, 
CuI (5.4 g, 28.4 mmol) and THF (150 mL) were added under inert 
atmosphere, and the mixture was stirred at rt for 5 minutes. The 
suspension was cooled at -78 ºC, and allyl magnesium bromide (28.4 
mL, 28.4 mmol of a 1 M solution in Et2O), TMSCl (3.6 mL, 28.4 
mmol), and crude 29 (7.11 mmol) unsaturated lactam in THF (5 mL) 
were successively added. The resulting mixture was stirred at -78 ºC 
for 18 h. The reaction was quenched with NH4Cl ss and filtered on 
Celite; followed an extraction of the aqueous layer with EtOAc , and 
dried on MgSO4. The organic layers were concentrated in vacuo and 
the residue was purified by FC (n-Hex/EtOAc 9:1  7:3), affording 
30 (2.1 g, 5.75 mmol, 81%) as a mixture of epimers at C-6. 
Major epimer 30a (6S)  
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1H NMR (300 MHz, CDCl3, COSY, gHSQC): H 7.33-7.26 (m, 5H, 
C6H5), 5.84 (dddd, J = 15.3, 9.9, 8.7, 5.1 Hz, 1H, CH=), 5.68 (dddd, J 
= 15.0, 10.2, 9.0, 4.8 Hz, 1H, CH=), 5.14 (m, 4H, CH2=), 4.91 (dd, J 
= 7.2, 1.8 Hz, 1H, H-3), 4.62 (d, J = 9.6 Hz, 1H, H-8a), 4.15 (dd, J = 
9.3, 7.2 Hz, 1H, H-2), 4.02 (dd, J = 9.3, 1.8 Hz, 1H, H-2), 3.60 (s, 3H, 
CH3O), 3.43 (d, J = 1.5 Hz, 1H, H-6), 2.70-2.44 (m, 3H, H-8, CH2 
allyl), 2.34 (d, J = 12.0 Hz, 1H, H-7), 2.16 (dt, J = 14.1, 9.3, 9.3 Hz, 
1H, CH2 allyl,), 1.80 (1 H, CH2 allyl, ddd, J = 14.1, 12.0, 9.0 Hz. 13C 
NMR (75.4 MHz, CDCl3): C 170.6, 162.3, 140.5, 134.8-134.4, 128.2, 
127.4, 116.5, 117.4, 89.4, 73.9, 59.6, 52.3, 51.5, 38.5, 36.9, 31.8, 31.6. 
IR (film): 1665, 1736 (CO) cm-1. HRMS (m/z): [M+H]+ calcd. for 
C21H25NO4, 356.1783; found 356.1779.  
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(3R,6aR,10aS,10bR)-Methyl-5-oxo-3-phenyl-
3,5,6,6a,7,10,10a,10b-octahydro-2H-oxazolo[2,3-a]isoquinoline-6-
carboxylate (31) 
 
In a two-neck round-bottom flask, second generation Grubbs catalyst 
(642 mg, 0.78 mmol) was added to a solution of lactam 6 (3.58 g, 10.1 
mmol) in DCM (1400 mL). The mixture was stirred at rt for 18 h and 
concentrated under reduced pressure. The crude of the reaction was 
purified by FC (n-Hex/EtOAc 4:1  3:2) affording product 31 (3.1 g, 
9.39 mmol, 93%) as a mixture of epimers at C-6. 
Major Epimer 31a (6R)  
1H NMR (400 MHz, CDCl3, COSY, gHSQC): H 7.35-7.22 (m, 5H, 
C6H5), 5.69 (m, 2H, H-8, H-9), 4.92 (dd, J = 6.9, 1.2 Hz, 1H, H-3), 
4.85 (d, J = 9.9 Hz, 1H, H-10b), 4.12 (dd, J = 9.0, 6.9 Hz, 1H, H-2), 
3.96 (dd, J = 9.0, 1.2 Hz, 1H, H-2), 3.60 (s, 3H, CH3O), 3.18 (s, 1H, 
H-6), 2.70 (m, 1H, H-10a), 2.50 (m, 1H, H-6a), 2.43 (m, 2H, H-10), 
2.20 (m, 1H, H-7), 2.00 (m, 1H, H-7). 13C NMR (100.6 MHz, CDCl3): 
C 170.2, 162.0, 140.6, 127.2, 128.0-126.8, 124.8-124.4, 87.1, 73.6, 
59.4, 53.9, 52.2, 33.5, 32.6, 28.0, 25.1. IR (film): 1667, 1738 (CO) 
cm-1. 
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(3R,6R,6aR,10aS,10bR)-Methyl-6-(2-(1,3-dioxolan-2-yl)ethyl)-5-
oxo-3-phenyl-3,5,6,6a,7,10,10a,10b-octahydro-2H-oxazolo[2,3-
a]isoquinoline-6-carboxylate (32) 
 
 
In a two-neck round-bottom flask, a solution of isoquinoline 31 (880 
mg, 2.69 mmol) in dry DMF (2 mL) was added to a cooled (0 ºC) 
suspension of NaH (60% dispersion in mineral oil, 161 mg, 4.03 
mmol) in anhydrous DMF under an inert atmosphere; the resulting 
mixture was stirred at 0 ºC for 1 h. 2(2-bromoethyl)-1,3-dioxolane 
(1.59 mL) and TBAI (198 mg, 0.54 mmol) were added at 0 ºC, and the 
mixture was stirred overnight at rt.The reaction was quenched by 
addition of NH4Cl saturated solution, and the mixture was extracted 
firstly with Et2O and then with DCM. The organic phases were dried 
on MgSO4, and the resulting phase was concentrated in vacuo. The 
crude was purified by FC (n-Hex/EtOAc 7:3  1:1) and afforded the 
product 32 (920 mg, 2.15 mmol, 80%). 
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1H-NMR (400 MHz, CDCl3): H 7.20-7.10 (m, 5H, ArH), 5.67 (m, 
2H, H-8, H-9), 4.92 (dd, J = 6.8, 1.6 Hz, 1H, H-3’), 4.90 (d, J = 9.6 
Hz, 1H, H-10b), 4.61 (t, J = 4.8 Hz, 1H, CH2CH2CHO2), 4.13 (dd, J = 
9.2, 6.8 Hz, 1H, H-2), 4.05 (dd, J = 9.2, 1.6 Hz, 1H, H-2), 3.80-3.75 
(2m, 4H, OCH2CH2O), 3.71 (s, 3H, CH3O), 2.58 (dd, J = 9.6, 4.8 Hz, 
1H, H-10a), 2.46 (m, 2H, H-10), 2.27 (ddd, J = 11.6, 5.6, 3.6 Hz, 1H, 
H-6a), 2.16 (tm, J = 17.2 Hz, 1H, H-7) 1.99 (m, 2H, CH2CH2CHO2), 
1.85 (dm, J = 17.2 Hz 1H, H-7), 1.44 (m, 2H, CH2CH2CHO2). 13C-
NMR (100.6 MHz, CDCl3): C 171.8, 165.1, 141.5, 128.3, 127.4, 
126.6, 124.6-124.3, 104.1, 87.0, 73.5, 64.6, 59.7, 58.4, 51.9, 40.0, 
33.4, 31.4, 29.4, 25.7-25.6. [α]22D= – 35.2 (c 0.7, CHCl3). HRMS 
(m/z): [M+H]+ calcd for C25H33NO5, 427.24; found  428.37.  
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(4R,4aR,8aS)-tert-butyl-4-(2-(1,3-dioxolan-2-yl)ethyl)-4-
(hydroxymethyl)-3,4,4a,5,8,8a-hexahydroisoquinoline-2(1H)-
carboxylate (37) 
 
First step: liquid ammonia was condensed at -78 ºC in a three-necked, 
100 mL round-bottomed flask, equipped with a coldfinger condenser 
and charged with dry-ice acetone; a solution of lactam 32 (200 mg, 
0.454 mmol) in THF (10 mL) was added. The temperature was raised 
at -33 ºC for 2 minutes and sodium metal was added in small portions 
until the blue color persisted. The mixture was stirred at -33 ºC for 2 
minutes. After this time, the reaction was quenched with solid NH4Cl 
until the blue color disappeared, and the solution was leave stirring at 
rt for about 2h. The residue was digested at rt with DCM and the 
resulting suspension was filtered on celite. The organic solvent was 
evaporated at reduced pressure and the crude afforded was employed 
for the next reaction without further purification. 
Second step: LiAlH4 (235 mg, 6.21 mmol in dioxane) was added 
dropwise under inert atmosphere at 0 C to a solution of the previous 
reaction in anhydrous dioxane (14 mL), and the mixture was stirred at 
  167 
reflux temperature overnight. After cooling the reaction at 0 ºC, it was 
quenched with distilled water (x3) and NaOH at 5%. Take care during 
this process and add water only when argon flux is open; Na2SO4 is 
added as solid in the reaction flask. The crude was filtered through 
celite and the solvent was reduced in vacuo. The yellow oil obtained 
was used in the next step without any further purification. 
Third step: Di-tert-butyl-dicarbonate (98 mg, 0.455 mmol) was 
added dropwise to a solution of the previous amino alcohol in 
anhydrous DCM (7 mL) at rt under inert atmosphere, and the resulting 
mixture was stirred for 20 h. Saturated aqueous NH4Cl was added. The 
aqueous phase was extracted with DCM and the organic phases were 
collected and washed with a saturated aqueous solution of NaCl, dried 
on MgSO4. 
The crude was purified by FC (n-Hex/EtOAc 9:1  1:1) and afforded 
the molecule 37 in 45% (75 mg, 0.204 mmol) overall yield. 
 
1H NMR (400 MHz, CDCl3): H 5.60 (m, 2H, H-6 H-7), 4.87 (t, J = 
4.8 Hz, 1H, CH2CH2CHO2), 3.98 -3.85 (2m, 4H, OCH2CH2O), 3.62-
3.59 (m, 2H, H-1, H-3), 3.42 (s, 2H, CH2OH), 2.77-2.67 (m, 2H, H-1, 
H-3), 2.30-1.98 (m, 4H, H-5, H-8, H-8a), 1.96-1.78 (m, 2H, H-8, H-
4a), 1.76-1.58 (4H, CH2CH2CHO2, m), 1.45 (s, 9H, (CH3)3C). 13C 
NMR (100.6 MHz, CDCl3): C 124.8, 104.7, 79.5, 68.2, 64.9, 45.4, 
34.2, 28.4, 27.9, 27.21, 24.0, 21.6. [𝒂]𝑫
𝟐𝟐: -8.34 (c 0.44, DCM). HRMS 
(m/z): [M+Na]+ calcd for C20H33NO5, 390.2251; found 390.2263. 
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(4R,4aR,8aS)-tert-butyl-4-(2-(1,3-dioxolan-2-yl)ethyl)-4-
(azidomethyl)-3,4,4a,5,8,8a-hexahydroisoquinoline-2(1H)-
carboxylate (39) 
 
 
First step: in a two-neck round-bottom flask, anhydrous Et3N (2.18 
mL, 15.6 mmol) and MsCl (1.21 mL, 15.6 mmol) were added at 0 ºC 
under inert atmosphere to a stirred solution of alcohol 37 (1.98 g, 5.21 
mmol) in dry DCM (86 mL), and the resulting mixture was stirred at 
rt for 4h. The reaction was quenched adding aqueous saturated NH4Cl 
solution, and extracted with DCM/H2O; the collected organic phases 
were dried on MgSO4 and the volume reduced in vacuo. The resulting 
mesylate 38 was obtained as yellow oil and was used in the next step 
without purification. 
Second step: NaN3 (2.03 g, 31.2 mmol) was added to a solution of the 
previous mesylate 38 in dry DMF (15 mL), and the mixture was heated 
to 90 ºC. After 48 h, more NaN3 (2.03 g, 31.2 mmol) was added and 
the resulting mixture was stirred at 90 ºC for an additional 24 h. The 
reaction was quenched by adding distilled water. The aqueous layer 
was extracted with DCM and the organic layers were dried on MgSO4; 
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solvent volume was reduced in vacuo. The mixture was purified by 
FC (n-Hex  n-Hex/EtOAc 1:1) yielding azide 39 (1.6 g, 4.12 mmol, 
79%). 
 
1H NMR (400 MHz, CDCl3): H 5.48 (m, 2H, H-6, H-7), 4.72 (t, J = 
4.8 Hz, 1H, H-3’,), 3.85- 3.72 (2m ,4H, OCH2CH2O), 3.62-3.59 (m, 
2H, H-1, H-3), 3.10 (m, 2H, CH2N3), 2.63-2.49 (m, 2H, H-1, H-3), 
2.08-1.88 (m, 4H, H-5, H-8, H-8a), 2.08-1.44 (m, 10H, H-1’, H-2’ H-
8, H-4a, H-5, H-8a), 1.35 (s, 9H, (CH3)3C). 13C NMR (100.6 MHz, 
CDCl3): C 124.5, 123.9, 104.6, 79.6, 64.8, 44.1, 43.3, 39.7, 34.7, 28.3, 
27.7, 25.7, 21.5. [𝒂]𝑫
𝟐𝟐: -35.18 (c 0.595, CH2Cl2). HRMS (m/z): 
[M+Na]+ calcd for C20H32N4O4, 415.2316; found 415.2334.  
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(4S,4aS,6S,8aS)-tert-butyl-4-(2-(1,3-dioxolan-2-yl)ethyl)-7-
hydroxy-9-tosyloctahydro-6,4-(epiminomethano)quinoline-
1(2H)-carboxylate (42) 
 
 
First step: in a two-neck round-bottom flask, m-chloroperoxybenzoic 
acid (317 mg, 1.84 mmol) was added to a cold solution (0 ºC) of azide 
39 (327 mg, 0.83 mmol) in DCM (12 mL); the mixture was allowed 
to warm slowly to rt. After 5 h the reaction was quenched adding an 
aqueous solutions of 1:1 NaHCO3 and saturated Na2S2O3, than 
extracted firstly with Na2SO3 10% and secondly with DCM. The 
organic extracts were dried on MgSO4 and concentrated in vacuo, to 
yield the azido epoxide 40, used in the next step without purification. 
Second step: Me3P (1.33 mL, 1.33 mmol) was added to a solution of 
the azido epoxide 40 in THF (16 mL) and H2O (16 mL), and the 
mixture was stirred at rt overnight. The diazatricyclic intermediate 41 
was obtained after evaporation of the organic phase in vacuo. 
Third step: Et3N (0.12 mL, 0.83 mmol) was added dropwise to a 
stirring solution of the aminoalcohol 41 in dry DCM (14 mL) at 0 ºC. 
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A solution of p-toluensulfonyl chloride (158 mg, 0.83 mmol) in dry 
DCM was transferred via cannula and the stirring continued at 0 ºC 
for about 2.5/3 h. The reaction was quenched by adding saturated 
aqueous NH4Cl solution and the aqueous layer was extracted with 
DCM. The combined organic extracts were dried on MgSO4 and 
concentrated in vacuo. The raw material was purified by FC (n-
Hex/EtOAc 9:1  1:1) to afford the protected tricyclic compound 42 
(89 mg, 0.166 mmol, 20%). 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): H 7.64 (d, J = 8.2 Hz, 
2H, H-o Ts), 7.22 (d, J = 8.1 Hz, 2H, H-m Ts), 4.60 (s, 1H, H-3’), 3.96 
(s, 1H, H-6), 3.90 (hidden signal, 2H, H-1, H-3), 3.86 (m, 2H, CH2O), 
3.83 (hidden signal, 1H, H-7), 3.76 (m, 2H, CH2O), 3.24 (d, J = 12.9 
Hz, 1H, H-10), 3.03 (d, J = 12.5 Hz, 1H, H-10), 2.78-2.60 (m, 2H, H-
1, H-3), 2.33 (s, 3H, CH3Ts), 1.97 (m, 1H, H-8a), 1.92 (d, J = 16.0 Hz, 
1H, H-5), 1.64-1.59 (m, 3H, 2H-8, H-5), 1.45 (m, 1H, H-4a), 1.41-
1.35 (m, 13H, (CH3)3C, H-1’, H- 2’). 13C NMR (100.6 MHz, CDCl3): 
C 155.3, 143.3, 137.6, 129.9, 127.2, 104.4, 80.0, 67.3, 64.8, 50.8, 
49.6-48.4, 46.8, 35.2, 32.4, 32.3, 30.7, 29.4, 28.2, 27.3, 21.9, 21.1. 
[𝒂]𝑫
𝟐𝟐: = +24.01 (c 1.5, CHCl3). HRMS (m/z): [M+H]+ calcd for 
C27H40N2O7, 537.2629; found 537.2613.  
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(4S,4aS,6S,8aS)-tert-butyl-4-(2-(1,3-dioxolan-2-yl)ethyl)-7-oxo-9-
tosyloctahydro-6,4-(epiminomethano)quinoline-1(2H)-
carboxylate (43) 
 
 
In a two-neck round-bottom flask, Dess-Martin periodinane (840 mg, 
1.98 mmol) was added to a solution of alcohol 42 in DCM at 0 °C. 
The reaction was stirred overnight at rt. After this time aqueous 
saturated solutions 1:1 of NaHCO3 and NaS2O3 were added, and the 
resulting mixture was extracted with DCM. The organic layer was 
dried on MgSO4 and concentrated under reduced pressure. The crude 
was purified by FC (n-Hex  n-Hex:EtOAc 1:1) and afforded 
oxidized product 43 (910 mg, 1.70 mmol, 86%). 
 
1H NMR (400 MHz, CDCl3, COSY, HSQC): H 7.70 (d, J = 8. Hz, 
2H, H-o Ts), 7.70 (d, J = 8. Hz, 2H, H-o Ts), 7.23 (d, J = 8.0 Hz, 2H, 
H-m Ts), 4.85 (s, 1H, H-3’), 4.35 (s, 1H, H-6), 3.98 (m, 2H, CH2O), 
3.86 (m, 2H, CH2O), 3.76-3.55 (br, 3H, H-1, H-3, H-10), 2.78-2.59 
(br, 3H, H-1, H-3, H-10), 2.48-2.42 (m, 1H, H-5), 2.37 (s, 3H, CH3Ts), 
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2.35-2.29 (m, 1H, H-8), 2.11 (s, 1H, H-8a), 1.72- 1.63 (m, 3H, H-4a, 
H-8, H-5), 1.58-1.54 (2H, H-2’, m), 1.41-1.32 (m, 11H, (CH3)3C, H-
1’). 13C NMR (100.6 MHz, CDCl3): C 205.1, 155.0, 143.5, 134.4, 
129.8, 127.0, 104.1, 80.1, 64.9, 56.9, 50.8-47.2, 47.0, 43.1, 36.3, 34.1, 
29.4, 29.1, 28.2, 27.5, 21.4. IR (film): 1715 (C=O) cm-1, 1688 (C=O) 
cm-1. [𝒂]𝑫
𝟐𝟐: +12.46 (c 3.15, CHCl3). HRMS (m/z): [M+NH4]+ calcd 
for C28H40N2O7S, 566.2894; found 566.2894. 
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B2.8 Synthesis of Fragment C-13/C-20 
 
3-Bromo-1-(tert-butyl)dimethylsilyloxy)propane (48) 
 
 
 
In a two-neck round-bottom flask, Et3N (3,6 mL, 26.0 mmol), DMAP 
(122 mg, 1.0 mmol), and TBDMSCl (3.6 g, 26.0 mmol) were added 
to a solution of 3-brome-1-propanol (1.8 mL, 20 mmol) in dry THF 
(30 mL). After stirring for 18 h at rt, aqueous saturated solution of 
NH4Cl was added. The aqueous phase was extracted with DCM, the 
organic layer collected dried on MgSO4 and, in the end, concentrated 
under reduced pressure. The mixture of products was purified by FC 
(n-Hex  n-Hex/EtOAc 8:2) and yielded the product 48 (4.86 g, 19.2 
mmol, 96%). 
 
1H NMR (400 MHz, CDCl3): H 3.73 (t, J = 5.4 Hz, 2H, H-3), 3.51 (t, 
J = 6.6 Hz, 2H, H-1), 2.03 (m, 2H, H-2), 0.90 (s, 9H, (CH3)3C), 0.07 
(s, 6H, (CH3)2Si). 13C NMR (100.6 MHz, CDCl3): C 60.4, 35.5, 30.7, 
25.9, 18.3, 5.4. 
  
  175 
(3-((Tert-butyldimethylsilyl)oxy)propyl)triphenylphosphonium 
bromide (49) 
 
 
In a two-neck round-bottom flask, solid PPh3 was added, in inert 
atmosphere, to a solution of protected alcohol 48 (4.0 g, 15.9 mmol) 
in dry benzene (3 mL); the resulting mixture was stirred at 85 °C for 
18 h. The reaction was allowed to cool at rt, and Et2O was added; the 
volume of the solvent was reduced in vacuo. The crude was purified 
by FC (n-Hex  DCM/MeOH 9:1) and afforded the phosphonium salt 
49 (7.9 g, 15.26 mmol, 96%). 
Mp: 216 °C.  
 
1H NMR (300 MHz, CDCl3): H 7.90-7.69 (m, 15H, C6H5), 3.98 (m, 
4H, H-1, H-3), 1.95 (m, 2H, H-2), 0.85 (s, 9H, (CH3)3C), 0.04 (s, 6H, 
CH3Si).  
13C NMR (100.6 MHz, CDCl3): C 134.9, 133.7-130.3, 118.8-118, 
61.8-61.6, 2.1-26.0, 25.9, 19.2-18.7, 18.2, 5.3. HRMS (m/z): [M+H]+ 
calcd for C21H22OP–TBDMSi, 321.1403; found  321.1398.  
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Methyl-(Z)-8-((tert-butyldimethylsilyl)oxy)oct-5-enoate (50) 
 
 
In a two-neck round-bottom flask, NaHMDS (21.36 mL of a 1 M 
solution in THF, 21.36 mmol) was added dropwise, under inert 
atmosphere at -30 ºC, to a solution of the phosphonium salt 49 (10 g, 
19.42 mmol) in THF (240 mL) and toluene (48 mL). The orange 
reaction was stirred for 5h and 30’ at -30 ºC. A solution of the aldehyde 
46 (5.05 g, 38.83 mmol) in THF (20 mL) was added at -78 ºC; the 
reaction was allowed to warm at rt and was leave stirring overnight. 
Aqueous saturated NH4Cl was added and the mixture was extracted 
with EtOAc. The organic phase was dried on MgSO4 and was 
evaporated under reduced pressure. Product 50 (4.7 g, 16.5 mmol) was 
afforded after FC purification (n-Hex  n-Hex:EtOAc 8:2) in 85% 
yield. 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): H 5.40 (m, 2H, H-5, 
H-6), 3.67 (s, 3H, CH3O), 3.60 (t, J = 6.4 Hz, 2H, CH2OSi), 2.31 (t, J 
= 8.0 Hz, 2H, H-2), 2.25 (m, 2H, H-7), 2.08 (m, 2H, H-4), 1.69 (m, 
2H, H-3), 0.89 (s, 9H, (CH3)3CSi), 0.05 (s, 6H, (CH3)2Si). 13C NMR 
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(75.4 MHz, CDCl3): C 174.1, 130.3-126.9, 62.9, 51.5, 33.5, 31.1, 
26.7, 25.9, 24.8, 18.3, 5.3. IR (film): 1742 (COO) cm-1. HRMS (m/z): 
[M+H]+ calcd for C15H30O3Si, 287.2000; found 287.2042. 
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Methyl-(Z)-8-bromooct-5-enoate (52) 
 
 
 
Mesylation step: in a two-neck round-bottom flask, Et3N (190 L, 
1.35 mmol) and MsCl (130 L, 1.8 mmol) were added at 0 C, to a 
solution of alcohol 50 (135 mg, 0.9 mmol) in dry DCM (12 mL). The 
reaction was allowed to warm at rt and was stirred for 2 h. Aqueous 
saturated NH4Cl was added to quench the reaction, and the phase was 
extracted with DCM. The organic layer was dried on MgSO4 and 
evaporated in vacuum. The mesylate intermediate was obtained in 
99% yield after FC purification (n-Hex-EtOc 8:2  6:4). 
Bromination step: under inert atmosphere, a solution of LiBr (2.9 g, 
33.3 mmol) in THF (13 mL) was added to a solution of previous 
mesylate (818 mg, 3.33 mmol) in DCM (9.3 mL) at 0 °C. The reaction 
was stirred overnight at rt. The reaction was quenched by addiction of 
distilled H2O and the aqueous phase was extracted with DCM. The 
organic layer was dried on MgSO4 and the volume reduced in vacuo. 
Derivative 52 was yielded (587 mg, 2.5 mmol, 75%) after FC 
purification (n-Hex  n-Hex/EtOAc 3:7). 
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1H NMR (300 MHz, CDCl3): H 5.56 (m, 1H, CH=), 5.41 (1H, CH=, 
m), 4.21 (t, J = 6.8 Hz, 2H, H-8), 3.67 (s, 3H, CH3O), 2.55 (qd, J = 
7.2, 1.2 Hz 2H, H-7), 2.36 (t, J = 7.2 Hz, 2H, H-2), 2.14 (m, 2H, H-4), 
1.71 (m, 2H, H-3). 13C NMR (100.6 MHz, CDCl3): C 173.8, 132.6, 
69.0, 51.5, 37.4, 32.2, 27.3-26.6, 24.5. IR (film): 1730 (COO) cm-1. 
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(Z)-[(8-Methoxycarbonyl)-3-octen-1-yl]triphenylphosphonium 
bromide (53) 
 
 
In a two-neck round-bottom flask, PPh3 (113 mg, 0.43 mmol) was 
added under inert atmosphere to a solution of 52 (100 mg, 0.43 mmol) 
in dry benzene (1.2 mL). Reaction was stirred for 18 h at 85 C, then 
allowed to cool at room temperature. After removal of organic phase 
under reduced pressure, the crude was purified by FC (n-Hex  
DCM:MeOH) yielding the phosphonium salt 53 (201 mg, 0.40 mmol, 
94%). Once this product was obtain, before its use in the further 
reaction, was dried under vacuum connected to a P2O5 system. 
 
1H NMR (400 MHz, CDCl3): H 7.92-7.67 (m, 15H, C6H5), 5.65 (m, 
1H, CH=), 5.38 (m, 1H, CH=), 4.00 (m, 2H, H-8), 3.60 (s, 3H, CH3O), 
2.43 (m, 2H, H-7), 2.21 (t, J = 7.2 Hz, 2H, H-2), 1.85 (2H, H-4, q, J = 
7.6 Hz), 1.57 (m, 2H, H-3). 13C NMR (100.6 MHz, CDCl3): C 173.9, 
135.0-134.9, 131.0, 133.8-133.7-130.5-130.4, 127.4-127.2, 118.8-
117.9, 51.4, 33.2, 26.5, 24.4, 23.2, 20.3. 
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B2.9 Synthesis of Fragment C-21/C-32 
 
(Triisopropyloxy)-3-butane (55) 
 
 
In a two-neck round-bottom flask under inert atmosphere, TIPSCl (8.2 
g, 42.8 mmol) was added at 0 C to a stirred solution of imidazole (3.3 
g, 48.5 mmol) and but-3-yn-1-ol (2 g, 28.53 mmol) in dry DMF (7 
mL). The mixture was then allowed to warm at rt and stirred for 4 h. 
An aqueous saturated solution of NH4Cl was added to quench the 
reaction. The aqueous phase was extracted with DCM and the organic 
layer was dried on MgSO4 and the volume reduced in vacuo. 
Purification by FC (n-Hex  n-Hex/EtOAc 9:1) afforded the 
protected alcohol 55 (5.75 g, 25.39 mmol) in 89% yield. 
 
1H NMR (400 MHz, CDCl3): H 3.80 (t, 2H, H-1), 2.42-2.38 (m, 2H, 
H-2), 1.92 (s, 1H, H-4), 1.11-1.03 (m, 21H, TIPS-H). 13C NMR (100.6 
MHz, CDCl3): C 81.30, 69.24, 62.03, 31.62, 22.90, 17.90, 11.97. 
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5-((Triisopropylsilyl)oxy)pent-2-yn-1-ol (57) 
 
 
In a two-neck round-bottom flask, under inert atmosphere at -78 C, 
n-BuLi (11.1 mL, 27.66 mmol) was added to a solution of protected 
alcohol (5.68 g, 25.25 mmol) in dry THF (72 mL). The reaction was 
stirred for 15’ and was allowed to warm at 0 C. HCHO was added 
(830 mg, 27.66 mmol) and reaction was warmed at rt and stirred for 5 
h. HCl 1 M was added and the mixture was extracted with Et2O. The 
crude was purified by FC (n-Hex  n-Hex/EtOAc 8:2) and afforded 
product 57 (5.63 g, 21.96 mmol) in 87% yield. 
 
1H NMR (400 MHz, CDCl3): H 4.25-4.23 (m, 2H, H-5), 3.80 (t, 2H, 
H-1), 2.49-2.45 (tt, 2H, H-2), 1.12-1.07 (m, 21H, TIPS-H). 13C NMR 
(100.6 MHz, CDCl3): C 83.18, 62.05, 51.13, 23.13, 17.86, 11.91. 
  183 
9-((Triisopropylsilyl)oxy)nona-3,6-diyn-1-ol (58) 
 
 
 
First step: in a two-neck round-bottom flask, TsCl (4.145 g, 21.77 
mmol) was added to a solution of the alcohol 57 (4.65 g, 18.14 mmol) 
in Et2O (91 mL) at 0 C. KOH (5.08 g, 90.12 mmol) was added and 
the reaction was stirred for 2 h. Aqueous saturated solution of NH4Cl 
was added and the mixture was extracted with EtOAc/brine and the 
organic phase was dried on MgSO4. Solvent was evaporated under 
reduced pressure. Tosylated product was used in the next reaction 
without further purification. 
Second step: to a solution of the protected intermediate in dry DMF 
(91 mL), K2CO3 (3.76 g, 27.21 mmol), CuI (3.45 g, 18.14 mmol), NaI 
(2.72 g, 18.14 mmol) and, in the end, but-3-yn-1-ol (1.32 g, 18.09 
mmol) were added, and the mixture was stirred overnight at 40 C. 
The reaction was quenched by addiction of aqueous saturated solution 
of NH4Cl. The mixture was firstly filtered on celite, and once the two 
phases were separated they were extracted with Et2O. The resulting 
organic layer was evaporated in vacuo. Product 58 (4.80 g, 15.55 
mmol) was afforded through FC (n-Hex  n-Hex/EtOAc 85:15) in 
86% yield. 
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1H NMR (400 MHz, CDCl3): H 3.76 (t, 2H, H-1), 3.67 (t, 2H, H-9), 
3.11 (m, 2H, H-5), 2.44-2.37 (m, 4H, H-2, H-8), 1.10-1.02 (m, 21H, 
TIPS-H). 13C NMR (100.6 MHz, CDCl3): C 75.18, 70.97, 62.15, 
61.04, 23.12-23.05, 17.90, 11.93, 9.71. 
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 (3Z,6Z)-9-((Triisopropylsilyl)oxy)nona-3,6-dien-1-ol (59) 
 
 
In a three-neck round-bottom flask, NaBH4 (425 mg, 11.24 mmol) was 
added portionwise to a stirred solution of Ni(OAc)2 x 4 H2O (2.4 g, 
9.55 mmol) in dry MeOH (191 mL) at rt under inert atmosphere. 
Argon atmosphere was replaced with H2 and a purple coloration was 
appreciated. EDA was added and the mixture was stirred for 30’. After 
addition of starting material (1.73 g, 5.62 mmol) in anhydrous MeOH 
(14 mL), other 2 h passed before quenching the reaction. The mixture 
was filtered on celite and washed with Et2O. The volume of the 
organic phase was reduced and re-extracted with brine and DCM. The 
intermediate was used in the next two reaction without further 
purification. 
 
1H NMR (400 MHz, CDCl3): H 5.55-5.31 (m, J = 9.15, 5.76, 4.34, 
1.66 Hz, 4H, H-3, H-4, H-6, H-7), 3.71 (t, 2H, H-1), 3.14 (t, 2H, H-9), 
2.82 (t, 2H, H-5), 2.67 (q, 2H, H-2), 2.31 (q, 2H, H-9), 1.13-1.04 (m, 
21H, TIPS-H). 13C NMR (100.6 MHz, CDCl3): C 130.57, 128.90, 
128.14, 126.67, 63.01, 31.47-31.29, 25.94, 18.08, 11.99.
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([(3Z,6Z)-9-Iodo-1-[(triisopropylsilyl)oxy]-3,6-nonadien (61) 
 
 
 
First step: in a two-neck round-bottom flask, the reduced alcohol 
(1.73 g, 5.62 mmol) was cooled at 0 °C in DCM (14 mL). Et3N (295 
mg, 7.87 mmol) was added, followed by MsCl (269 mg, 6.74 mmol). 
After stirring 2 h, an aqueous saturated solution of NH4Cl was added 
and the mixture was extracted with DCM, dried over MgSO4 and the 
volume reduced in vacuo. The crude was used in the next reaction 
without further purification. 
Second step: in a solution of the mesylate intermediate in dry acetone 
(34 mL), NaI (3.37 g, 22.48 mmol) was added and the mixture was 
stirred at reflux temperature for 2 h. The reaction was allowed to cool 
at room temperature, and after addition of brine and a saturated 
solution of tiosulphate the aqueous layer was extracted with hexane. 
Purification of the crude by FC (n-Hex  n-Hex/EtOAc 95:5) 
afforded the iodine derivate 61 (1.52 g, 3.60 mmol) in 64% overall 
yield. 
 
1H NMR (400 MHz, CDCl3): H 5.43-5.37 (m, J = 9.15, 5.76, 4.34, 
1.66 Hz, 4H, H-3, H-4, H-6, H-7), 3.83 (t, 2H, H-1), 3.17 (t, 2H, H-9), 
2.63 (t, 2H, H-5), 2.53 (q, 2H, H-2), 2.15 (q, 2H, H-9), 1.13-1.04 (m, 
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21H, TIPS-H). 13C NMR (100.6 MHz, CDCl3): C 131.3, 128.8, 
125.67, 64.10, 31.7, 25.6, 22.10, 17.90, 5.20. 
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B2.10 Synthesis of the model 
 
2-(3-Cyclohexenyl)ethanol (64) 
 
 
 
In a two-naked round-bottom flask, BF3∙Et2O (7.5 mL, 61 mmol) was 
added dropwise over 30 minutes under inert atmosphere, to a cooled 
(0 ºC) solution of 2-methyl-2-butene (61 mL of a 2 M solution in THF, 
122 mmol) and NaBH4 (1.2 g, 44.4 mmol) in anhydrous THF (28 mL), 
and the resulting mixture was stirred at 0 ºC for 1 h. 4-
vinylcyclohexene (6 g, 55.5 mmol) was then added dropwise over a 5 
minutes and the solution was stirred at rt for 2 h. The borane 
intermediate was oxidized by slowly addition at 0 ºC of NaOH 3N (50 
mL) and H2O2 30% (50 mL), and the resulting solution was stirred 
overnight at 70 ºC. The resulting mixture was extracted with Et2O and 
combined organic extract were dried over Na2SO4, filtered, and 
concentrated under reduced pressure affording alcohol 64 in 95% 
yield (6.65 g, 52.7 mmol). 
 
1H NMR (400 MHz, CDCl3, COSY, gHSQC): H 5.65 (m, 2H, H-1, 
H-2), 3.71 (t, J = 6.8 Hz, 2H, H-2’), 2.11 (dm, J = 14.8 Hz, 1H, H-3), 
2.05 (m, 2H, H-6), 1.72 (m, 2H, H-4, H-5), 1.69 (dm, J = 14.8 Hz, 1H, 
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H-3), 1.54 (m, 2H, H-1’), 1.26 (m, 1H, H-5). 13C NMR (100.6 MHz, 
CDCl3): C 127.0-126.0, 60.8, 39.4, 31.7, 30.1, 28.8, 25.0. IR (film) 
3400 (OH) cm-1. HRMS (ESI): [M+H]+ calcd for C8H14O, 127.1117; 
found: 127.1114. 
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4-(2-Azidoethyl)cyclohexene (66) 
 
 
 
In a two-neck round-bottom flask, Et3N (1.0 mL, 7.0 mmol) and MsCl 
(680 L, 9.26 mmol) were added dropwise to a stirring solution of 
alcohol (584 mg, 4.63 mmol) in anhydrous DCM (58 mL) cooled to 0 
ºC under inert atmosphere. After the end of addition, the mixture was 
allowed to heat slowly to rt and was stirred for additional 2 h. Aqueous 
saturated solution of NH4Cl was added as quenching and the mixture 
was extracted with DCM. The combined organic layers were dried 
over anhydrous Na2SO4, filtered and the solvent was concentrated in 
vacuo. The crude was purified by FC (n-Hex/EtOAc 99:1  95:5) and 
the azide 66 (658 mg, 4.35 mmol, 94%) was obtained as colourless 
oil. 
 
1H NMR (400 MHz, CDCl3): H 5.66 (m, 2H, H-1, H-2), 3.33 (t, J = 
6.9 Hz, 2H, H-2’), 2.05 (m, 3H, 2H-6, H-3), 1.80-1.53 (m, 5H, H-5, 
H-4, H-3, 2H-1’), 1.29 (m, 1H, H-5). 13C NMR (100.6 MHz, CDCl3): 
C 126.9-125.8, 49.1, 35.1, 31.3, 30.8, 28.4, 24.8. 
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8-Hydroxy-2-(p-toluenesulfonyl)-2-azabicyclo[3.3.1]nonane (68) 
 
 
 
First step: in a two-neck round-bottom flask, m-chloroperoxybenzoic 
acid (5 g, 29 mmol) was added to a cold solution (0 ºC) of azide (1.5 
g, 10 mmol) in DCM (102 mL); the mixture was allowed to warm 
slowly to rt. After 4 h the reaction was quenched adding an aqueous 
solution of 1:1 NaHCO3 and saturated Na2S2O3, then extracted firstly 
with Na2SO3 10% and secondly with DCM. The organic extracts were 
dried on Na2SO4 and concentrated in vacuo, to yield a mixture of 
epoxides, used in the next step without purification. 
Second step: Me3P (12.5 mL, 12.55 mmol) was added to a solution of 
the azido epoxide (10.0 mmol) in THF/H2O (170 mL, 6:1), and the 
mixture was stirred at rt overnight. The diazatricyclic intermediate was 
obtained as a pale oil after evaporation of the organic phase in vacuo. 
Third step: Et3N (2.4 mL, 17.2 mmol) was added dropwise to a 
stirring solution of the aminoalcohol (15.6 mmol) in dry DCM (156 
mL) at 0 ºC. A solution of p-toluensulfonyl chloride (3.87 g, 20.3 
mmol) in dry DCM was transferred via cannula and the stirring 
continued at 0 ºC for about 4 h. The reaction was quenched by adding 
saturated aqueous NH4Cl solution and the aqueous layer was extracted 
with DCM. The combined organic extracts were dried on MgSO4 and 
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concentrated in vacuo. The raw material was purified by FC (n-Hex 
n-Hex/EtOAc 1:1) to afford the protected tricyclic compound 68 
(2.95 g, 8.58 mmol, overall yield 55%). 
 
1H NMR (400 MHz, CDCl3): H 7.70 (d, J = 8.1 Hz, 2H, H-o Ts), 7.30 
(d, J = 8.1 Hz, 2H, H-m Ts), 4.10 (br. s, 1H, H-8), 3.75 (m, 1H, H-1), 
3.50 (q, J = 6.3 Hz, 1H, H-3), 3.18 (q, J = 6.3 Hz, 1H, H-3), 2.43 (s, 
3H, CH3Ts), 1.26-2.05 (m, 9H, 2H-4, 2H-9, H-5, 2H-6, 2H-7). 13C 
NMR (100.6 MHz, CDCl3): C 143.2, 136.8, 129.6, 127.1, 68.7, 53.3, 
40.9, 27.6, 25.8, 24.1, 23.3, 21.4. IR (film) 3600 (OH) cm-1. 
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8-Oxo-2-(p-toluenesulfonyl)-2-azabicyclo[3.3.1]nonane (69) 
 
 
 
In a two-neck round-bottom flask, Dess-Martin periodinane (604 mg, 
1.42 mmol) was added at the temperature of 0 C, to a solution of the 
above alcohol (171 mg, 0.58 mmol) in DCM (19.5 mL). The reaction 
was allowed to reach rt and was stirred overnight. After this time 
aqueous saturated solutions 1:1 of NaHCO3 and Na2S2O3 were added, 
and the resulting mixture was extracted with DCM. The organic layer 
was dried on MgSO4 and concentrated under reduced pressure. The 
crude was purified by FC (n-Hex  n-Hex:EtOAc 1:1) and afforded 
oxidized product 69 (41 mg, 0.139 mmol, 24%). 
 
1H NMR (400 MHz, CDCl3): H 7.65 (d, J = 8.0 Hz, 2H, H-o Ts), 7.28 
(dd, J = 8.0, 0.8 Hz, 2H, H-m Ts), 4.21 (t, J = 2.8 Hz, 1H, H-1), 3.65 
(dt, J =12.4, 6.0 Hz, 1H, H-3), 3.27 (m, 1H, H-3), 2.41 (s, 3H, CH3 
Ts), 2.28 (m, 2H, H-7), 2.12 (m, 3H, H-5, H-4, H-9), 1.95 (m, 1H, H-
6), 1.84-1.89 (m, 3H, H-4, H-9, H-6). 13C NMR (100.6 MHz, CDCl3): 
C 207.7, 143.5, 129.5, 127.6, 59.2, 40.6, 38.1, 33.1, 30.6, 29.8, 23.6, 
21.5. IR (film) 1716 (C=O) cm-1. HRMS (m/z): [M+H]+ calcd for 
C15H19NO3S, 294.1158, found: 294.115.   
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